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Our understanding of tumors as complex organs has increased our appreciation for
each component of the tumor microenvironment and its respective contribution to
tumorigenesis. Fibroblasts found within a tumor actively participate in the growth,
progression and metastasis of cancer cells. Senescent fibroblasts, which are permanently
arrested yet metabolically active, accumulate in tissue over time where they may promote
the proliferation and malignant conversion of preneoplastic cells in older individuals. I
have examined the relationship between senescent fibroblasts and preneoplastic
keratinocytes and identified the secreted multifunctional protein osteopontin (OPN) as a
critical stromal mediating factor. RNAi-directed reduction of stromal OPN leads to
decreased growth of preneoplastic keratinocytes in vitro and in vivo. Furthermore, I have
demonstrated the presence of senescent stroma and associated OPN expression in the
early stages of a chemical carcinogenesis mouse model, suggesting that it plays a role
early in tumor formation. OPN is part of a unique transcriptional profile activated upon

ii

senescence induction. Given the significance of senescent stromal-derived factors in
tumorigenesis, I have investigated the regulation of OPN and other members of the
senescence-associated secretory profile (SASP). I demonstrate that SASP is coordinately
upregulated in response to multiple stimuli inducing senescence namely DNA damage,
chromatin modulation and ectopic expression of p27, a cyclin-dependent kinase inhibitor.
However, my work on the transcriptional activation of OPN reveals that SASP contains
distinct subsets governed by unique transcriptional mechanisms.

To this end, I

demonstrate that OPN, unlike IL6 and IL8 – two well characterized SASP members –
does not require the activity of ATM or NfκB for its expression in senescence. To
uncover specific activators of OPN transcription, I examined OPN’s promoter and I
identified a fragment that is responsive in senescent fibroblasts.

Furthermore, I

demonstrate that OPN transcription requires chromatin modulators. Together my work
presents a model where chromatin modifications in senescence play a central role in
dictating transcriptional responses that ultimately impact the tumor microenvironment.
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Chapter 1: Background and Significance

1

1.1 Significance and Overview
Tumorigenesis is the result of cell autonomous alterations in the incipient tumor
cell and alterations in the surrounding tissue. Elegant work in vitro has demonstrated that
disruption of five essential pathways is sufficient to transform a normal cell [1].
Specifically, deregulation of tumor suppressor function, acquisition of constitutive
mitogenic stimulus, disruption of protein phosphatase 2A function and acquisition of
cellular immortality by stabilization and maintenance of telomeres is sufficient to
transform normal human cells [1]. Despite the cell-autonomous changes driving
transformation, research in the recent decade has demonstrated that a tumor operates as a
complex organ consisting of multiple cell types with each contributing to tumor
progression. Such intricate balance and interaction is required for malignant progression
and metastasis.

1.2 The tumor microenvironment
The earliest descriptions of the tumor microenvironment involved components of
the immune system. It was presumed that the immune system’s main function in
tumorigenesis was protective; however, some of its arms given the right molecular cues
are potent accomplices in malignancy. Mounting evidence supports the pro-tumorigenic
role of macrophages, which can be “trained” by the microenvironment to stimulate the
growth of epithelial cells. To this end, presence of tumor associated macrophages
(TAMs) has prognostic value with higher infiltration correlating with poor patient
outcome [2]. Similar observations have been made for neutrophils found within a
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malignant lesion [3]. Likewise, other elements of the immune system such as B cells,
which constitute among the highest infiltrate in tumors, are critical for transformation and
progression in well-characterized skin cancer models [4]. The complexity of the
interactions in the tumor microenvironment is best illustrated by the elegant crosstalk
between the adaptive and innate arm of the immune system. In one model, B cells found
within the tumor release soluble immunoglobulin thereby mediating the recruitment of
mast cells and pro-tumor macrophages [5]. Infiltration of innate immune cells induces
enhanced neoplastic cell proliferation and angiogenesis and contributes to metastasis.
Growing research on the tumor microenvironment has revealed an extensive array of
paracrine players including adipocytes [6] and endothelial cells [7]. The
microenvironment is composed of these cell types, which convert classically anti-tumor
mechanisms into pro-tumor devices.
Identifying and elucidating the molecular actions of stromal-derived factors is
valuable not only to functionally unravel molecular pathways involved in tumorigenesis,
but also to identify molecular markers for diagnosis and therapy. In the past, tumor
profiling consisted of collecting whole tumor tissue without separating tumor cells from
the surrounding stroma thus generating a generic genetic landscape. However, with the
advent of laser capture microdissection technology, it is possible to separate the tumor
stroma from the epithelial cells. Surprisingly, this approach had recently yielded a
genetic signature that is more reliable in predicting patient outcome than the classical
signatures hitherto used [8]. Gene expression comparison of stroma found within the
margin of invasive breast tumors to stroma distant to the tumor revealed a 26-gene
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signature referred to as the stroma-derived prognostic predictor (SDPP). Application of
SDPP to existing data sets collected from whole tumors accurately identified patients
with a poor outcome. Furthermore, the stromal signature reflects different biological
inputs including the immune system, fibroblastic response and extracellular matrix
remodeling possibly facilitating the identification of patients that will benefit from certain
therapies.
The impetus for generating stromal signatures was based on fundamental work
performed on tumor microenvironmental constituents. A decade ago, fibroblasts isolated
from a tumor (hereafter referred to “cancer-associated fibroblasts – CAFs”) were shown
to be potent promoters of tumorigenesis [9]. CAFs from prostate cancers, as opposed to
fibroblasts isolated from normal prostate, stimulated the growth of initiated prostate
epithelial cells – the latter were isolated from dysplastic prostate tissue showing no signs
of carcinoma. CAFs altered the morphology of the initiated epithelial cells, protected
them from death signals and increased their proliferation.

In xenografts, CAFs

contributed to enhanced tumors. Another seminal finding of the above study highlighted
a critical aspect of the relationship between epithelial cells and activated stroma. When
CAFs were incubated with normal prostate epithelial cells, although some morphological
alterations occurred in the epithelial cells, there was no increased proliferation or tumor
growth indicating that the response to activated stroma requires existing genetic
mutations in the epithelium – an uninitiated epithelium is refractory to aberrant signaling
emanating from the stromal compartment. Presently, it is unclear what mutations enable
the epithelium to respond to paracrine stimulation.
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While the origin of CAFs is still unknown (they could be derived from bone
marrow progenitor cells or educated by the local milieu) and their genetic identity is
controversial (opposing views contend whether CAFs have somatic mutations or result
from epigenetic reprogramming) [10-12], their active role in tumorigenesis is
undisputable. Following the Olumi et al study [9], numerous reports have demonstrated
that CAFs have an altered expression profile enriched in growth factors, chemokines,
extracellular matrix (ECM) remodeling enzymes and angiogenic factors. Indeed, this has
lead to the argument that CAFs behave as myofibroblasts – an activated fibroblast that
orchestrates tissue remodeling during wound healing [13].
The list of CAF-derived factors vested with tumor-altering properties is extensive:
to this end, it was shown that stromal-derived factor 1 (SDF-1), which is overexpressed in
CAFs acts upon epithelial cells inducing proliferation; moreover, it recruits from the bone
marrow other components of the tumor microenvironment such as endothelial progenitor
cells (EPCs) thus enhancing angiogenesis [14]. A variety of chemokines such as IL6,
CCL5 and CXCL14 enlist elements of the immune system, which as described above
play an active role in tumor progression. Mitogenic factors including EGF, HGF, PDGF
and IGF promote the proliferation of cancer cells and enhance their survival. Abundant
secretion of ECM remodeling enzymes such as matrix metalloproteinases (e.g. MMP2, 3,
9) and crosslinking enzymes (LOX) ensures the cooperation of the microenvironment for
migration and invasion [15]. In fact, activated fibroblasts establish a migratory track for
cancer cells thus mediating invasion and metastasis [16]. These and other molecular
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processes not mentioned here underscore the fibroblasts as active participants in
tumorigenesis.
The extensive profiling of cancer-associated fibroblasts and their role in
tumorigenesis drew attention to another class of fibroblasts that had been studied for a
long time in culture: senescent fibroblasts. Hayflick’s seminal work demonstrated that
primary cells such as fibroblasts have a finite lifespan (also referred to as the Hayflick
limit) [17]. Later this “clocking” mechanism was identified as the telomere [18], which
prevented the cell from undergoing an infinite number of divisions unless telomerase (the
telomere extending enzyme) was present such as is the case with cancer cells.
Furthermore, exposure to nonphysiological conditions such as abnormal oxygen levels,
cellular stress or the presence of oncogenes translates into a permanent arrest
indistinguishable from the Hayflick limit.

All of these features had been well

characterized in culture but it was not until recently that an array of elegant studies taking
advantage of improved detection techniques and markers has demonstrated that senescent
cells are indeed viable in tissue and perform important functions (to be discussed later).
One of the best accepted markers of senescence to date (although limited) is
senescence-associated β-galactosidase. Originally described by Dimri et al [19] over a
decade ago, it has become a universal indicator of senescence. In addition to being able
to discriminate between quiescent or terminally differentiated cells and senescent cells,
the authors reported an age-dependent increase in the number of senescent cells in
samples of human skin suggesting senescent cells accumulate with age [19]. Although
the number of senescent cells in tissue varies widely, the original findings have found
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support in subsequent studies using additional markers of senescence such as telomere
dysfunction or activation of the DNA damage response that clearly demonstrate an
increase of senescent cells with age and in association with some pathologies [20, 21].

1.3 Senescence as a phenomenon of antagonistic pleitropy
While the link between senescence and organismal ageing is still debatable, the
increased presence of senescent cells with age is well-established [21]. Additionally, the
correlation between ageing and cancer onset is well established [22]. Indeed, the single
largest risk factor for cancer is age. The molecular basis for increased cancer as a
function of age remains incompletely understood. The cell autonomous mutation theory
partially explains the increased cancer risk with the accumulation of mutations over time;
however it has become clear that the surrounding environment is not a bystander in this
process and can accelerate tumorigenesis. Pioneering work by Campisi and colleagues
began to address the link between cancer and ageing by exploring the role of senescent
fibroblasts given their accumulation in ageing and their “tumor-promoting” profile.
Human primary fibroblasts driven to senescence either by replicative exhaustion,
oncogene overexpression (Ras), induction of a tumor suppressor (p14 – ARF), or
treatment with hydrogen peroxide were shown to enhance proliferation of epithelial cells
in coculture systems in vitro and to stimulate tumor formation in xenografts [23]. This
finding indicated that senescent in fibroblasts function as a potent paracrine tumor
promoter. Similar to the original findings with CAFs, senescent fibroblasts only
promoted the growth of premalignant and malignant epithelium but not normal epithelial
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cells. Strikingly, paracrine stimulation occurred even when only ten percent of the
fibroblast population was senescent and it employed both cell-cell contact and secreted
factors [23].
The observation that senescence acts as a tumor promoter in a paracrine setting
was groundbreaking because senescence was previously considered a tumor suppressor
given it inhibits proliferation by permanently arresting cell proliferation. It has been
argued that this is a classical example of evolutionary antagonistic pleiotrophy:
senescence is beneficial early in life where it constitutes a potent anti-tumor mechanism
within incipient tumor cells, but becomes detrimental in ageing due to its ability to alter
the microenvironment and promote tumorigenesis [23]. The validity of senescence as a
tumorigenesis barrier within the epithelial compartment has been confirmed by several
studies. For example Eµ-N-Ras transgenic mice develop invasive lymphomas much
earlier when they harbor deletions in the Suv39h1 (histone methyltransferase) or p53
locus and are unable to induce senescence. In contrast, Eµ-N-Ras mice with a wild type
background display non-lymphoid neoplasias at a significant delay, which show signs of
senescence [24] indicating that heterochromatin- and p53-mediated senescence stalls
tumor formation.
Likewise, oncogene-induced senescence (OIS) initiated by BRAFV600E expression
is found in human nevi, which display robust senescence markers and rarely progress to
malignancy arguing that OIS is encountered physiologically and acts as a tumor barrier
[25]. OIS was further shown to be a distinguishing characteristic of premalignant lesions
(adenomas) and absent in malignant ones (adenocarcinomas). Meticulous profiling of the
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progressing tumors delivered a histochemical signature of senescence thus allowing a
more accurate diagnosis of senescence in vivo [26]. Finally, Pandolfi and colleagues
demonstrated that the acute loss of PTEN results in senescence and late onset
premalignant prostate lesions, whereas the combined loss of PTEN and p53 accelerates
tumorigenesis and ensuing death by abrogating senescence. The rodent studies were
supported by the identification of senescent cells in human prostate premalignant lesions
[27]. These revolutionary studies heralded an era of active research in senescence as a
physiological tumor-preventing mechanism [28, 29].
While on the surface, senescence may appear to have contradictory roles – both
suppressive and promoting (Figure 1.1) – it is no different than other well-studied
phenomena that are context dependent such as organismal immunity discussed earlier.
The initial findings describing senescence as a putative promoting player in the tumor
microenvironment were followed by closer examination of the expression profile of
senescent fibroblast and their properties.

Thus work from several groups has

demonstrated that senescent fibroblasts secrete a plethora of growth factors such as
amphiregulin, which is important for the proliferation of premalignant prostate epithelial
cells [30]. Moreover, some growth factors originating from the tumor cells such as
growth-regulated oncogene 1 (Gro-1) can induce senescence in neighboring fibroblasts
generating a stroma conducive to further malignant progression [31].

Gro-1 is

overexpressed by ovarian cancer cells and examination of human ovarian tumors
revealed the presence of senescent stroma adjacent to the tumor suggesting that such
cross-talk is present in human tumors.
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Prominent inflammatory chemokines like IL6 and IL8 have become the hallmarks
of what is now termed the senescence-associated secretory phenotype or SASP [32]. Not
only do these chemokines act on neighboring epithelial cells by inducing proliferation
and invasion and presumably on immune cells, but they are also components of a
feedback mechanism reinforcing senescence [33]. Additionally, senescent stromalderived MMP3 has been shown to promote branching of preneoplastic mammary
epithelial cells and invasion in three-dimensional assays [34]. In another report, MMPs
were responsible for the early growth advantage of xenografts injected with senescent
fibroblasts [35]. In addition to mitogens and ECM remodeling enzymes, senescent
fibroblasts also secrete proangiogenic factors such as vascular endothelial growth factor
(VEGF), which may explain their ability to enhance endothelial cell invasion through a
basement membrane [36]. Another outcome of paracrine signaling originating from
senescent fibroblasts is increased radioresistance and drug resistance in the cancer cells
underscoring senescent fibroblasts as potential therapeutic targets [37].

1.4 Osteopontin as a senescent stromal-derived factor
The above studies, demonstrating the ability of senescent fibroblasts to affect
multiple growth parameters in the tumor microenvironment, provided the impetus to
dissect the molecular mechanisms of cross-talk in the microenvironment. Examination of
the expression profile of senescent fibroblasts in different systems has revealed some
convergence. However, we performed independent microarray analysis in order to
capture a transcriptional signature reflected by the culture conditions used in our system
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(serum-free). This work led to the identification of osteopontin (OPN) [38], which is the
focus of my thesis work. The following chapters will summarize my findings, but below
I provide a basic introduction to osteopontin and its known functions in tissue
homeostasis and its role in tumorigenesis.
OPN is a secreted protein with pleiotropic functions. Initially identified in the late
1970s as a protein associated with transformation [39], OPN is embedded abundantly in
the bone matrix contributing to its calcification and ECM stability in addition to affecting
osteoclast differentiation and bone resorption [40]. Later, its role in the immune system
was characterized where it modifies inflammatory responses in a context-dependent
fashion by its ability to act as a chemoattractant for macrophages, dendritic cells and T
cells and enhances immunoglobulin production by B cells [41]. The outcome of OPN
signaling in the immune system points to its role as a general “stress sensor” ultimately
coordinating actions to control the damage response in tissue [40]. This model is
supported by the unrestrained infections and inflammatory phenotype observed in the
OPN null mouse [41], yet elevated levels of OPN have been reported in several
pathologies associated with inflammation (e.g. Crohn’s disease) affirming the complex
and context-dependent role of OPN [42, 43].
The cytokine-like properties of OPN are most evident in tumorigenesis. OPN
interacts with a multitude of receptors such as integrins (αvβ1/β3/β5 and α4β5/β8 and α9β1)
and particular variants of CD44 (v6 and v7). These interactions result in the activation of
numerous signaling pathways leading to increased cell survival, proliferation,
angiogenesis, cell motility and metastasis [44] hence, it is no surprise that OPN is
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considered a prognostic marker for several malignancies [45]. In addition to multiple
receptor utilization, signaling versatility is provided by the extensive array of
modifications such as phosphorylation, cleavage by thrombin and several MMPs, and Nand O-linked glycosylation, which impact OPN function in a cell and tissue-dependent
fashion. OPN’s role in tumorigenesis is further supported by the lower incidence and
delayed appearance of lesions in OPN-/- mice in a two-stage chemical carcinogenesis
model [46]. Moreover, a recent finding identifies OPN secreted by cancer cells as a
systemic pro-tumor effector. Actively growing tumors stimulate the proliferation of
indolent tumor cells located in distant sites via the recruitment and local integration of
bone marrow cells (BMCs). Systemic secretion of OPN by the growing tumors was
responsible for the recruitment of BMCs and the subsequent proliferation of indolent
tumor cells. Thus OPN impacts tumor growth not only locally but also systemically
implicating it in micrometastases and recurrence [47].
Most of the studies conducted thus far have focused on epithelial-derived OPN
highlighting its multifaceted roles in biology. However, it has already been mentioned
that the stroma, represented mainly by immune cells [48], is a significant source of OPN
in the microenvironment raising the possibility that fibroblast-derived OPN is an
important contributor to tumorigenesis. This is based on several lines of evidence.
Expression of platelet-derived growth factor (PDGF) by tumor cells induces recruitment
of CAFs, which in turn augment tumor growth and angiogenesis via OPN [49].
Furthermore, OPN is a validated member of the stroma-derived prognostic predictor
(SDPP) signature described earlier, thus solidifying its connection with stromal
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involvement in tumorigenesis [8]. The potential role of senescent stromal-derived OPN
as a paracrine effector of tumorigenesis will be addressed in Chapter 2 of this thesis.

1.5 Pathways and transcription factors involved in the senescence program
Given that senescent cells play a pivotal role in preneoplastic cell growth, it is
critical to understand how senescent cells activate OPN and the rest of the senescent
associated secretory phenotype (SASP). These molecules have a profound effect on the
remodeling of the microenvironment, yet little is known as to their regulation in
senescence.

We and others have demonstrated that the secretory program is a

transcriptional response [32, 33, 38, 50]. Thus far, our analysis suggests that these genes
are coordinately regulated and that their expression is linked to the senescence program.
Therefore, it follows that transcription factors required for the induction and maintenance
of senescence may be responsible for the upregulation of the paracrine effectors as well.
The p53 and Rb pathways are essential for senescence in human cells [51]. Upon major
assaults such as critical telomere shortening, excessive DNA damage, aberrant mitogenic
stimulation or other types of cellular stress, p53 is stabilized via different mechanisms
(acetylation, phosphorylation, degradation of inhibitors [52]. Through its activation of
p21 or through the direct control of other targets such as cyclins and associated kinases,
p53 accomplishes cell cycle arrest and senescence.
In human cells, absence of p53 alone does not jeopardize entry into senescence
due to the presence of signaling emanating from the p16-Rb pathway [53]. p16 is
activated by a variety of stimuli – it inhibits cyclin-dependent kinases 4 and 6, therefore
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blocking the phosphorylation of Rb .
repressing proliferation [54].

Hypophosphorylated Rb interacts with E2F

In several cell types (but not all) senescence is

accompanied by distinct heterochromatic domains known as senescence-associated
heterochromatic foci (SAHFs), which occupy E2F-controlled promoters and are
dependent on p16/Rb [55, 56].

In addition to Rb, other proteins contribute to

heterochromatin present in SAHFs. Histone chaperones HIRA and ASF-1 translocate to
PML bodies upon a senescence trigger and this localization is a preliminary step required
for SAHFs formation [57, 58]. SAHFs contain other nonhistone protein classes: HP1,
which is enriched in heterochromatic regions containing H3K9-me3 contributing to
chromatin assembly and epigenetic modifications; and unexpectedly HMGA proteins
usually associated with proliferation [55, 56]. Such facultative heterochromatinization
enforces a permanent cellular arrest and may explain the classic insensitivity to mitogenic
stimuli observed in senescent cells. It is yet unclear as to whether SAHFs are a cause or
consequence of senescence, although work mentioned previously demonstrates that
histone methyltransferases are required for senescence induction in vivo [24].
Such chromatin changes in senescence are not surprising given the long-known
nuclear architecture and chromatin aberrations observed in cells isolated from patients
with premature ageing syndromes or aged model organisms consisting of loss of
heterochromatic structure, reduction of HP1, global decrease in methylation, decrease in
deacetylase activity, redistribution of silencing complexes and persistent DNA damage
([59] and references therein) accompanied by significant changes in gene expression
patterns with an overrepresentation of stress response genes [60]. While the trigger for
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the above changes is not known, these phenomena are interlinked as chromatin relaxation
activates components of the DNA damage response (DDR) [61] and DNA breaks alter
surrounding chromatin [62] – both processes impact transcription [59]. A recent
surprising finding is that DDR activates a transcriptional response not directly associated
with the repair of the breaks themselves in developing lymphocytes [63] raising the
intriguing possibility that a similar phenomenon occurs in senescence. In fact, both
replicative senescence (due to dysfunctional telomeres) [64] and OIS (due to
hyperreplication) [65, 66] are characterized by robust DDR activation, which has been
implicated in the maintenance of the senescent state. Recent work has suggested that
such signaling is also important for the activation of a subset of SASP factors [67].
Currently, it is unclear whether OPN is under the same regulatory mechanisms described
above; therefore, I undertook to investigate the interplay between DDR and chromatin
and their putative role in the transcriptional regulation of OPN and other SASP
components. This work will be addressed in Chapter 3.
In addition to p53 and Rb, other transcription factors have been invoked in the
establishment of senescence and the secretory phenotype associated with it (Figure 1.3).
C/EBPβ, a bZIP transcription factor, translates extracellular cues into proliferative,
tumorigenic, arresting, differentiation and metabolic responses.

It is activated

downstream of physiologic Ras signaling [68]. In a similar fashion, it is activated by and
required for the execution of oncogene-induced senescence (OIS) in mouse embryonic
fibroblasts [69]. Recent reports demonstrate that this is the case in human cells as well.
OIS (BRAFV600E or Mek-driven) in human fibroblasts upregulates the levels of C/EBPβ,
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which enforces cellular arrest via its transcriptional control of cytokines such as IL6 and
IL8 [33, 50]. As already noted, senescent cells have a pronounced inflammatory profile
and one of the main transcription factors involved in cytokine production and
inflammation is NfκB [70], which cooperates in the activation of SASP [50, 71]. Thus,
the inflammatory transcriptome partially controlled in senescence by C/EBPβ and NfκB
fulfills a dual mission: 1) maintains the permanent arrest by a self-amplifying secretory
loop; and 2) modifies the surrounding microenvironment thereby promoting
tumorigenesis.
The transcriptional regulation of OPN is complex and context-dependent
reflecting its role in diverse physiological processes. A cursory examination of the
human OPN promoter reveals binding sites for multiple transcription factors [72], a few
of which occupy these sites in vivo. Based on previous work analyzing the OPN
promoter and the abovementioned literature about transcriptional control in senescence, I
postulated that some of these mechanisms governed OPN transcription; however, I also
decided to undertake a nonbiased, classical promoter analysis approach: I investigated
OPN promoter activity in senescent cells, identifying the responsive fragment and
transcription factor binding sites contained therein. Information derived from this study
and the subsequent experiments are contained in Chapter 3 and Appendix 1 and 2. This
work reveals layers of regulation in OPN and SASP transcription, highlighting points of
convergence but also uniqueness.
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1.6 Summary
The more we delve into a physiological process, the more we realize biology is
multi-faceted and highly plastic. We are yet at the beginning of understanding the
molecular mechanisms of senescence induction and enforcement and its biological
implications but significant strides have been made in this direction.

Senescent

fibroblasts have been shown to promote preneoplastic epithelial growth and formation of
tumors in vivo, while their genetically identical young counterparts cannot. Even though
senescent fibroblasts are genetically normal, they appear to play a role in tumorigenesis
in a paracrine fashion. These observations indicate that senescent fibroblasts may be a
critical component of the tumor microenvironment. Additionally, they may provide an
experimental basis that links ageing and cancer. Conversely, senescent cells have been
shown to accumulate with age as do preneoplastic cells [21] (cells that carry mutations
that are not on their own sufficient to transform the cell); therefore, the two may come
into proximity of each other increasing the opportunity for a crosstalk between senescent
stroma and initiated epithelium. Such interactions may contribute to progression to full
tumorigenesis. If we are to understand how the stromal compartment contributes to the
transformation process we must identify factors that modulate the growth of
preneoplastic cells. This work will have a substantial impact in our understanding of
carcinogenesis, particularly in aged individuals. In addition, because this work focuses
on the genetically normal stromal compartment it may identify novel anti-neoplastic
targets that are less likely to be lost to genetic mutation; a problem often encountered
when targeting the cancer cell itself.
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Figure 1.1 Dual role of senescence in tumorigenesis
Upon telomere erosion or cellular stress, cells engage the senescence response, which
results in a proliferative arrest and an altered expression profile. In a tissue setting, an
oncogenic assault triggers checkpoint activation and senescence. Such genetic assaults
accumulate over time leading to an increase in preneoplastic cells. Those preneoplastic
cells that evade the senescence checkpoints are now primed to progress to malignancy.
Similarly, senescence is triggered in the stroma as a function of acute and cumulative
stress. In fact senescent fibroblasts alter the surrounding microenvironment by secreting
matrix remodeling proteins and growth factors thus contributing to the transformation
process. Evasion of senescence by the would-be tumor cell in combination with a
promoting stroma leads to tumorigenesis.
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Figure 1.2 Structure of the human osteopontin protein. Osteopontin contains multiple
phosphorylation and glycosylation sites. Additionally, OPN is subject to cleavage by
thrombin, which reveals a cryptic “SVVYGLR” site that is recognized by α4β1 and α9β1.
Matrix metalloproteases, MMP3 and 7 also cleave OPN, yielding several smaller
fragments reported to have differential activity. Each of these modifications impact OPN
activity in a tissue and context-dependent manner thus mediating a vast array of
biological outcomes [41].
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Figure 1.3 Regulatory mechanisms in senescence
Activation of the DNA damage response (DDR) upon DNA breaks or chromatin
modifications results in induction of senescence mediated by p53. Although, p53 is
required to establish senescence, it stifles the senescence-associated secretory response
(SASP) [32]; whereas, NfκB and C/EBPβ directly transcribe SASP promoters [50]. It is
currently unknown how these transcription factors are activated in senescence
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Abstract
Alterations in the tissue microenvironment collaborate with cell autonomous
genetic changes to contribute to neoplastic progression.

The importance of the

microenvironment in neoplastic progression is underscored by studies demonstrating that
fibroblasts isolated from a tumor stimulate the growth of preneoplastic and neoplastic
cells in xenograft models. Similarly, senescent fibroblasts promote preneoplastic cell
growth in vitro and in vivo. Because senescent cells accumulate with age, their presence
is hypothesized to facilitate preneoplastic cell growth and tumor formation in older
individuals. To identify senescent stromal factors directly responsible for stimulating
preneoplastic cell growth, we carried out whole genome transcriptional profiling and
compared senescent fibroblasts to their younger counterparts. We identified osteopontin
(OPN) as one of the most highly elevated transcripts in senescent fibroblasts.
Importantly, reduction of OPN protein levels by RNAi did not impact senescence
induction in fibroblasts; however, it dramatically reduced the growth-promoting activities
of senescent fibroblasts in vitro and in vivo, demonstrating that OPN is necessary for
paracrine stimulation of preneoplastic cell growth.

In addition, we found that

recombinant OPN was sufficient to stimulate preneoplastic cell growth. Finally, we
demonstrate that OPN is expressed in senescent stroma within preneoplastic lesions that
arise following DMBA/TPA treatment of mice, suggesting that stromal-derived OPNmediated signaling events impact neoplastic progression.
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Introduction
Age is the greatest risk factor for the development of neoplasia [1, 2]. The
molecular and physiologic factors that underlie age-related increases in cancer incidence
are diverse and include cell autonomous genetic and epigenetic alterations and coincident
alterations in the tissue microenvironment. Genetic analysis of human cancers has
revealed a myriad of mutations that disrupt diverse cellular signaling pathways. Cell
culture systems and murine models have demonstrated that disruption of pathways that
regulate tissue homeostasis, cell growth, cell survival/death and invasiveness cooperate to
produce a transformed cell [3-5]. While these cell autonomous alterations are critical to
tumorigenesis, preneoplastic and neoplastic lesions arise within the context of a complex
stromal compartment that consists of numerous cell types. Among these are epithelial
cells, fibroblasts, immune cells, and cells that contribute to angiogenesis that together
work to enable transformation.
The importance of the host microenvironment in the tumorigenic process is
supported by numerous studies. For example, it has been shown that chickens infected
with the Rous sarcoma virus develop tumors at sites of injury [6] and that activation of
mast cells enhances transformation in a skin model of carcinogenesis [7]. These studies
suggest that the inflammatory response plays a key role in tumorigenesis.

In further

support of this hypothesis, other studies have demonstrated that the chronic inflammation
caused by H. pylori infection or Crohn’s disease predisposes affected individuals to
cancer [8, 9].

In addition to inflammatory cells, fibroblasts can also promote

tumorigenesis.

Under normal conditions, fibroblasts are responsible for matrix
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deposition and reorganization and facilitate recruitment of cells that participate in tissue
homeostasis. However, fibroblasts present within neoplastic lesions display altered
expression profiles compared to fibroblasts isolated from normal tissues. Indeed, the
gene expression profiles found in cancer associated fibroblasts (CAFs) are reminiscent of
those found within a wound, and include expression of numerous growth factors,
chemokines, and angiogenic factors (reviewed in [10, 11]).

A role for CAFs in

promoting transformation was demonstrated in one study in which CAFs isolated from
prostate carcinomas were found to stimulate the in vitro and in vivo growth of
immortalized prostate epithelial cells whereas prostate fibroblasts distal to tumors had no
such capacity [12].
In addition to the increased mutational load and presence of preneoplastic cells
found to arise in aging epithelia, [13, 14], the stromal compartment also undergoes agerelated changes. Indeed, senescent cells accumulate in tissues with age [15-17]. Analysis
of senescent fibroblasts reveals a significantly altered gene expression profile relative to
their younger counterparts [18, 19]. Interestingly this altered gene expression profile
mirrors that observed during wound repair (reviewed in [10, 11]). Prominent among
genes whose expression is dramatically altered during wound repair are those that
remodel the extracellular matrix as well as growth factors and inflammatory cytokines.
Moreover, senescent fibroblasts function analogously to CAFs in that they promote the in
vitro and in vivo growth of preneoplastic cells [19, 20]. This latter observation suggests
that the age-related accumulation of senescent stromal cells and the alterations that they
produce within the tissue, collaborate with increasing numbers of preneoplastic cells to

31

influence cancer incidence in older individuals. However, how senescent stromal cells
function to promote tumorigenesis is still poorly understood because the panoply of
factors secreted by these cells has yet to be fully identified.
Our goal was to identify senescent stromal factors that impact preneoplastic cell
growth in order to begin to delineate the molecular mechanisms by which senescent
stroma functions in tumorigenesis. To this end, we performed expression profiling of
replicative senescent (RS [21]) fibroblasts and found that numerous factors were
coordinately modulated. This study identifies one of these factors, osteopontin (OPN) as
a critical mediator of stromal-epithelial interactions both in vitro and in vivo. We
demonstrate that OPN is sufficient to stimulate the growth of preneoplastic cells. Finally,
we show that senescent stroma expressing OPN can be found within premalignant lesions
in vivo, supporting the physiologic relevance of these results and the potential role of
OPN in promoting tumorigenesis.

Materials and Methods
Cell Lines. Human foreskin BJ fibroblasts and 293T cells were grown as previously
described [22]. HaCaT cells are spontaneously immortalized human keratinocytes; are
aneuploid, nontumorigenic and retain a near normal pattern of differentiation [23]. They
were grown in DME plus 10% heat-inactivated FCS. N.p.c.T human keratinocytes were
a kind gift from James Rheinwald (Harvard, MA) and were grown as previously
described [24]. N.p.c.T. are human epidermal keratinocytes that were derived from
newborn foreskin and transduced with human telomerase, mutant CDK4 (R24C) [24].
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These cells are immortal but retain the ability to undergo an epidermis-type suprabasal
differentiation program as evidenced by the ability to form a granular cell layer and an
enucleated stratum corneum [24].

Virus production and retroviral infections. Virus preparation as described [22].

Microarray analysis. BJ fibroblasts were mock or Bleomycin sulfate-treated (100ug/ml,
Sigma, St. Louis, MO) for 24 hrs. Replicatively senescent fibroblasts were obtained by
continuous passage. After 72 hr serum-starvation, RNA was collected using TRIzol
(Invitrogen, Carlsbad, CA). Biotinylated cRNA was hybridized to Affymetrix Human
Genome U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA) by the Washington
University Microarray Facility. There were 4, 6, and 6 samples for SIPS, RS, and young
respectively. Microarray quality control, analysis, and clustering (UPGMA by Centroid)
were performed using dChip (May, 2008 release) [25]. All GeneChip comparisons had a
cut-off basis of a lower bound of 90% confidence of fold-change ≥1.5 and expression
intensity difference ≥75. Gene Ontological categorization of probe sets was performed
using the Gene Ontology database, current to publication date. GO terms used: Immune
& Inflammation (IDs: 6955, 9615, 42742, 6952, 6954), Mitogens and Regulation of
Proliferation (IDs: 7067, 85, 45840, 86, 82, 45930, 7049, 45786, 187, 186, 1558, 8283),
Extracellular Matrix and Secreted Factors (IDs: 7596, 7160, 7155, 5604, 8243, 42730,
7596, 5201, 5581, 4252, 8237, 5125, 8008).

33

Co-Culture conditions. 1.2x104 fibroblasts were plated in 96 well plates (Fisher
Scientific, Pittsburgh, PA) and treated as described above. HaCaT- (1.0 x103) or N.p.c.T(2.0x103) CBR cells were plated on fibroblasts and incubated for 96 hr. Luciferase
(Chroma-Glo Luciferase System, Promega) readings were performed in a Bio Tek
microplate reader (Bio Tek Instruments, Winooski, VT).

OPN shRNA and Real-Time PCR. Three shRNA plasmids targeting the human OPN
gene sequence were provided in the pLKO.1 plasmid (sequences found on Mission
shRNA website; Sigma, St. Louis, MO). Standard protocol was followed for cDNA and
RT-PCR using the following primers: OPN, forward TTGCAGCCTTCTCAGCCAA and
reverse

CAAAAGCAAATCACTGCA

ATTCTC,

GAPDH,

forward

GCATGGCCTTCCGTGTCC, reverse AATGCCAGCCCCAGCGTCAAA.

OPN Immunoprecipitation. BJ fibroblasts plated in serum-free for 72 hrs. NETN lysis
buffer was added to media (20 mM Tris-HCl (pH 7.9), 1 mM EDTA, 100 mM NaCl, and
0.5% NP40) and incubated overnight at 4°C with OPN antibody (AF1433; R&D,
Minneapolis, MN).

Recombinant human OPN (rhOPN). HaCaT cells were plated in a 96 well plate
(1.0x103) and incubated in DME/F12 supplemented with 0.1% FCS for 24 hrs. 100
ng/ml rhOPN (R&D, Minneapolis, MN) was added for 72hrs. N.p.c.T cells were plated
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overnight (1.0x103) and 100ng/ml rhOPN was added in 5% K-sfm/DME/F12 (Invitrogen,
Carlsbad, CA) for 72 hrs.

Xenograft model and chemical carcinogenesis protocol. Female NOD/SCID mice
(NCI-Fredrick) were housed according to the guidelines of DCM, Washington University
School of Medicine. Live in vivo imaging as described [26]. Two-step chemical
carcinogenesis protocol as previously described [27] on 129S6/SvEv female mice
(Taconic, Germantown, NY). To obtain papillomas outbred transgenic mice (RBP-jflox/+
and K14CreERT; N1flox/+; RBP-jflox/+) were treated topically with DMBA (25ug) followed
by twice weekly TPA treatments (4ug) for 15 weeks starting one week after DMBA
treatment.

Senescent-associated β-galactosidase. Staining was performed on cells and 10um
frozen sections as previously described [16].

Immunohistochemistry. Dissected tissue was fixed for 1hr in 4% paraformaldehyde
and embedded in paraffin or OCT freezing medium (Sakura Finetek U.S.A, Torrance,
CA) and stained with the following antibodies: OPN 1:400 (AF808, R&D, Minneapolis,
MN); p16 1:50 (antigen retrieval in pH 9 Tris-buffer; sc-1661, Santa Cruz Biotechnology,
Santa Cruz, CA); CD45 1:60 (550539, BD PharMingen, San Diego, CA); F4/80
(MCA497G, Serotec, Raleigh, NC). Detection was visualized with Dako and Vector kits
(Dako, Carpinteria, CA and Vector, Burlingame, CA)
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Statistical Analysis. Data represent the mean ± SEM; statistical significance was
assessed by a two-tailed Student’s T-test.

Results
Senescent BJ fibroblasts stimulate the growth of preneoplastic cells in vitro and in
vivo. The tumor microenvironment is an important contributor to neoplastic progression
and an increasing body of evidence suggests that it also plays a pivotal role in the early
stages of the transformation process. One factor that impacts the stromal compartment is
age. Indeed, the presence of senescent cells increases with age [15-17] and these cells
possess the capacity to promote preneoplastic cell growth in several models [19, 20, 2830]. To address the molecular mechanism by which senescent fibroblasts mediate
preneoplastic cell growth, we first established a culture system that allowed us to
quantitate cell growth in vitro. Because the presence of senescent cells within the skin of
aging individuals increases with age [15-17] and our microarray analysis (see below) was
carried on human skin fibroblasts, we choose to utilize preneoplastic immortalized
keratinocytes (HaCaT and N.p.c.T.) for our studies [23, 24]. To facilitate quantification
of HaCaT and N.p.c.T. cell growth, we transduced them with click beetle red luciferase
(CBR) and grew them in the presence of young or senescent BJ fibroblasts. Senescence
can be induced by continued passage leading to replicative senescence (RS), which is
believed to be telomere based or by any number of other methods collectively referred to
as stress-induced premature senescence (SIPS) [19, 28, 31], all of which have been
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shown to stimulate the growth of preneoplastic cells [19, 20, 29, 30]. Therefore, we
chose to utilize bleomycin treatment, which reliably induces senescence of BJ skin
fibroblasts (Figure 2.1A). To confirm that cells undergoing RS and SIPS equivalently
stimulated preneoplastic growth, we compared their ability to stimulate the growth of
HaCaT cells. As shown in Figure 2.1B, RS and SIPS fibroblasts were equally proficient
at inducing the growth of HaCaT cells compared to HaCaT cells grown in the presence of
young BJ fibroblasts. In addition, live animal luciferase imaging revealed that BJ
fibroblasts undergoing RS or SIPS efficiently stimulated the growth of HaCaT xenografts
in vivo (Figure 2.1C and data not shown). Histological analysis of xenografts confirmed
that observed by our live animal imaging. Injection of HaCAT cells and senescent
fibroblasts resulted in large benign lesions. In contrast, injection of HaCAT cells alone or
in the presence of young fibroblasts resulted in small, nearly undetectable lesions (Figure
1D).

Analysis of the senescent transcriptome. Given the observed stimulation of HaCaT
cell growth after coculture with both RS and SIPS fibroblasts, we next carried out
microarray analysis to identify putative senescent-associated candidate genes. Given that
fibroblasts undergoing RS or SIPS similarly induced the growth of preneoplastic cells
[20] (Figure 2.1B), we hypothesized that a common core of genes was responsible for
their growth-promoting activities. Therefore, we conducted microarray analysis under
conditions that captured the cell culture conditions utilized in our coculture experiments
(i.e. serum-free and 3% O2). Using these conditions, RNA was isolated from BJ skin
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fibroblasts that had undergone RS or SIPS following bleomycin treatment and compared
the expression profile to young BJ fibroblasts.
Analysis of the resultant microarray data revealed a significant alteration in gene
expression in cells undergoing senescence versus their younger counterparts. As
expected, gene expression differences were observed between cells undergoing RS versus
SIPS. However, a significant overlap in the gene expression patterns of RS and SIPS
fibroblasts was apparent (Figure 2.2A). Indeed, when comparing genes differentially
expressed in each senescent population compared to young fibroblasts, 354 were
coordinately regulated in RS and SIPS fibroblasts (Figure 2.2B). GO analysis of the data
revealed that the coordinately regulated gene groups included proliferative and mitogenic
genes, genes involved in extracellular matrix (ECM) functions and inflammation (Figure
2.2C). Many of these genes code for secreted growth factors, chemokines, wound repair
proteins, and matrix remodeling proteins, which have been implicated in tumor stromaepithelial interactions [10, 11]. We also found that senescent fibroblasts increased
expression of AREG and MMP3, which impact preneoplastic cell growth and
morphology, respectively [19, 28]. These observations demonstrate that senescent
fibroblasts possess a significantly altered gene expression pattern compared to young
fibroblasts and supports the hypothesis that activation of senescence is likely to alter the
microenvironment, leading to enhanced preneoplastic cell growth and tumor formation in
a manner analogous to cancer associated fibroblasts (CAFs).
To validate our microarray results, we chose a subset of target genes based on
their reported secretory and mitogenic properties, reasoning that they would impact
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preneoplastic cell growth. Pregnancy-associated plasma protein A (PAPPA) is a
metalloprotease that cleaves insulin-like growth factor binding protein 4 (IGFBP4) – an
inhibitor of insulin growth factor (IGF) [32]. The direct result of PAPPA’s activity is
increased bioavailability of IGF, which is a potent growth-regulatory protein.
Amphiregulin (AREG) is a member of the epidermal growth factor family that stimulates
the growth and proliferation of epithelial cells. It was previously documented that AREG
is expressed in senescent fibroblasts and functions in a paracrine fashion to stimulate the
growth of prostate epithelial cells [19]. PAI-1, an inhibitor of tissue plasminogen
activator (tPA) and urokinase (uPA) was previously shown to mediate induction of
senescence [33].

Finally, we examined the expression of osteopontin (OPN), a

multifunctional secreted glycoprotein that has been implicated in diverse stages of
carcinogenesis (reviewed in [34]). qRT-PCR analysis verified the upregulation pattern
observed in the microarray for all of the selected genes (Figure 2.2D).

Identification of stromal-derived OPN in preneoplastic lesions coincident with
senescent stroma. Our microarray data indicated that OPN was significantly
upregulated in senescent fibroblasts, suggesting that it impacts preneoplastic cell growth.
OPN was originally identified as a transformation-associated matricellular protein
produced by cancer cells [35]. OPN is a secreted protein that is extensively modified by
phosphorylation and glycosylation [36] and is targeted by several metalloproteinases
[37]. While OPN contributes to mineralization and ECM integrity, it also functions as a
potent signaling cytokine [36]. Intriguingly, OPN-null mice display a significant delay in
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the appearance and incidence of papillomas in a classical two-stage skin chemical
carcinogenesis model [27], suggesting that OPN plays a key role in skin tumorigenesis.
To date, studies have focused on the function of epithelial-derived OPN in tumorigenesis
and its value as a prognostic marker [38]. However, given the high levels of OPN
expressed in senescent fibroblasts (Figure 2.2) and the delayed cancer phenotype
observed in OPN-null mice [27], we postulated that OPN expressed within the stromal
compartment contributes to the transformation process.
Given the possibility that stromal-derived OPN contributes to transformation, we
next sought to determine whether senescent stroma was present within a preneoplastic
lesion and whether it was coincident with OPN expressing cells. To address this
possibility, we took advantage of the two-stage skin carcinogenesis model. We choose to
focus on this model because previous studies demonstrated that 12-Otetradecanoylphorbol-13-acetate (TPA) treatment of murine skin leads to OPN expression
[39]. In addition, OPN null mice display a delayed tumor phenotype when treated with
this protocol [27]. To determine whether 7,12-dimethylbenz(a)anthracene (DMBA)
and/or TPA were sufficient to induce senescence, we first examined skin sections
obtained from mice that were treated with a single dose of DMBA followed by three
treatments of TPA. We utilized SA-βGal staining to assess the presence of senescent
cells. We observed the appearance of SA-βGal positive cells within the stromal
compartment of mice treated with DMBA and TPA as well as TPA alone (Figure 2.3A).
Remarkably, the appearance of senescent stroma precedes the presence of overt
hyperplasia as evidenced by the positive staining in TPA only-treated mice (AT) within 7
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days of treatment (Figure 2.3A). In addition, the same stromal area displayed p16positive cells, another senescent marker (Supplemental Figure 2.1). Using this model,
previous work demonstrated the presence of SA-βGal within the epithelial compartment
of papillomas that arose several months after the initial DMBA/TPA exposure [40].
While we see very limited SA-βGal staining within the epithelial compartment of the
skin, we postulate that the differences observed between our studies is due to the time at
which the tissue was analyzed. Indeed, in our hands SA-βGal staining of papillomas
arising several months after initial DMBA treatment did reveal limited staining within the
epithelial compartment (Supplemental Figure 2.2).
We next analyzed tissue from papillomas obtained from mice treated with a single
dose of DMBA followed by repeated twice-weekly treatments with TPA, which produces
papillomas at predictable latency [41]. As shown in Figure 2.3C (upper panel), OPN
staining within the stromal compartment of a papilloma coincided with p16 staining
while limited staining was observed within the epithelial compartment. In addition, we
also observed OPN positive cells in the stromal compartment of DMBA-TPA treated skin
adjacent to papillomas (Figure 2.3C lower panel). The presence of p16 expression is
consistent with the presence of senescent cells (16, 42). SA-βGal staining was also
evident within the stromal compartment of the papillomas, further supporting the
possibility that the OPN expression was within senescent stromal cells (Supplemental
Figure 2.2).
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Stromal-derived OPN stimulates the growth of preneoplastic cells. Senescent
fibroblasts possess growth-promoting activities that stimulate preneoplastic cell growth
[19, 20] and our data suggested that OPN functions as an important mediator of this
activity.

Therefore, to directly assess whether stromal-derived OPN impacted

preneoplastic cell growth, BJ fibroblasts were stably transduced with virally encoded
RNAi hairpin constructs targeting OPN or a control hairpin construct. We found that
knockdown of OPN in senescent fibroblasts by three independent hairpins (shOPN-7,
shOPN-8, and shOPN-9) resulted in dramatically reduced mRNA levels (Figure 2.4A)
and undetectable protein levels (Figure 2.4B) when compared to cells transduced with a
control hairpin (shSCR). Fibroblasts transduced with hairpins targeting OPN entered
senescence upon bleomycin treatment at the same rate as observed in control cells,
indicating that OPN expression is not necessary for induction of senescence (Figure
2.4C).
Having established that our RNAi constructs efficiently reduced OPN to
undetectable levels without impacting the induction of senescence, we next investigated
how loss of OPN impacted the growth-promoting properties of senescent fibroblasts.
Senescent fibroblasts mock transduced or transduced with a control hairpin (shSCR)
increased the growth of HaCaT and N.p.c.T cells compared to cells grown on young
fibroblasts (Figure 2.4D). In contrast, RNAi directed knockdown of OPN in senescent
fibroblasts resulted in a significant reduction in HaCaT and N.p.c.T cell growth (Figure
2.4D). Indeed, we found that loss of OPN resulted in HaCaT and N.p.c.T cell growth
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similar to that observed when these cells were plated on young fibroblasts, indicating that
OPN is necessary for stimulation of preneoplastic cell growth by senescent fibroblasts.

Stromal-derived OPN stimulates the growth of preneoplastic cells in xenografts.
Loss of OPN significantly reduced the growth promoting properties of senescent
fibroblasts in vitro. Therefore, we next addressed the impact of loss of stromal derived
OPN on the growth of HaCaT cells in xenografts. Utilizing live in vivo luciferase
imaging, we found that injection of HaCaT cells alone or in combination with young
fibroblasts resulted in little growth of xenografts. In contrast, coinjection of senescent
fibroblasts and HaCaT cells resulted in robust growth in vivo (Figure 2.5A). Similarly,
senescent fibroblasts expressing a control hairpin (shSCR) significantly stimulated
HaCaT cell growth. In contrast, OPN depletion abolished HaCaT cell growth indicating
that OPN derived from senescent fibroblasts is necessary in vivo (Figure 2.5A).
Immunohistological analysis of CD45 and F4/80 in xenografts revealed a decrease in
immune infiltration in lesions resulting from injection of senescent cells expressing a
hairpin targeting OPN versus a control hairpin (Figure 2.5B). Together, these
experiments indicate that stromal-derived OPN impacts the microenvironment and
significantly stimulates preneoplastic cell growth.

rhOPN is sufficient to stimulate the growth of preneoplastic cells. The above
experiments demonstrate that stromal-derived OPN significantly impacts preneoplastic
cell growth. We next sought to determine whether OPN is sufficient to promote
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preneoplastic cell growth. To address this question, we treated preneoplastic cells
(HaCaT/N.p.c.T) with recombinant human OPN (rhOPN) and measured its impact on cell
growth. We found that addition of rhOPN to both HaCaT and N.p.c.T cells conferred a
modest but significant growth advantage compared to mock-treated cells, indicating that
OPN acts as a paracrine factor that is sufficient for preneoplastic cell growth (Figure
2.6). The increased growth observed upon rhOPN treatment was less robust then when
HaCaT or N.p.c.T cells are plated directly on senescent fibroblasts expressing OPN
(Figure 2.4). Because senescent fibroblasts express numerous secretory proteins it is
possible that the reduced response observed upon rhOPN treatment reveals a requirement
for additional factors. Alternatively, the reduced response could be attributed to a lack of
adequate protein modifications on the rhOPN protein. As stated earlier, OPN is a highly
modified protein [42] and careful inspection of a longer exposure of our western blot
(Supplemental Figure 2.3) revealed the presence of additional OPN species in
supernatants obtained from senescent fibroblasts that were not present in the rhOPN
preparations.

Discussion
Alterations in the tissue microenvironment in combination with cell autonomous
mutations collaborate to drive the transformation process. Here, we identify osteopontin
(OPN) as a critical stromal-derived mediator of preneoplastic cell growth. Utilizing
microarray analysis we found that OPN is upregulated in senescent fibroblasts while
being undetectable in their younger counterparts. We found that senescent fibroblast-
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derived OPN was necessary for preneoplastic cell growth in vitro and in vivo. In
addition, recombinant OPN was sufficient to stimulate the growth of preneoplastic cells.
Finally, examination of papillomas that arose following treatment of mice with a
DMBA/TPA protocol revealed the presence of senescent stromal cells and OPN
expression within the stromal compartment. Taken together, our data argue that
senescent fibroblast-derived OPN contributes to tumorigenesis and reveal a previously
uncharacterized stromal function for OPN that may represent a novel therapeutic target
and/or biomarker for the early stages of cancer development.
Investigations into the cell types within the microenvironment that impact
tumorigenesis have revealed that macrophages, B and T cells, mast cells, adipocytes,
endothelial cells, and fibroblasts can affect primary growth and metastasis. Cancer
associated fibroblasts (CAF) exert their influence on neoplastic progression through
several mechanisms such as secretion of paracrine factors that directly stimulate cancer
cells and impact proliferation and survival. While senescent fibroblasts differ from CAFs
in regards to their proliferative capacity, they possess the ability to stimulate
preneoplastic and neoplastic cell growth in a manner analogous to CAFs [19, 20]. This
latter observation raises the possibility that the accumulation of senescent cells within
aged individuals alters the tissue microenvironment that in turn collaborates with cell
autonomous mutations to drive the transformation process. Intriguingly, we show that
senescent stroma appears before the emergence of a papilloma, arguing that stromal
changes arise early in the transformation process. In support of this hypothesis, our
microarray data indicate that in addition to OPN, senescent fibroblasts express numerous
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factors capable of remodeling the microenvironment and modulating cell growth in a
paracrine fashion. We propose that these early changes, which include the appearance of
senescent stroma and concomitant upregulation of OPN, provide a rich
microenvironment for tumorigenesis.
OPN is a pleiotropic protein to which numerous functions have been ascribed
including mineralization and calcification, osteoclast activation, endothelial cell survival,
wound healing, migration, lymphocyte proliferation and immunosurveillance [34].
Interestingly, in human cancer, OPN expression levels correlate with tumor grade and
elevated OPN serum levels is a poor prognostic indicator in a wide variety of tumors
[34]. Murine studies revealed that OPN null mice display a significant delay in
tumorigenesis when treated with the classic two-step skin carcinogenesis model of
DMBA/TPA treatment [27], suggesting that OPN plays a key role in cellular
transformation.
To date, investigation into OPN’s role in tumorigenesis has been limited to the
impact of epithelial-derived OPN on transformation and progression. However, a
functional role for stromal-derived OPN in tumorigenesis has not been investigated even
though other cell types including macrophages and neutrophils express OPN under both
normal and pathological conditions [43]. Notably, a recent microarray analysis of the
stromal compartment of human breast cancers identified osteopontin as one of twenty-six
genes that when overexpressed is a strong predictor of clinical outcome [44]. Our results
showing increased OPN in the stromal compartment of DMBA/TPA treated mice suggest
an even more general role for OPN in epithelial tumorigenesis. Together, these
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observations indicate that non-epithelial derived OPN is present at various stages of
tumorigenesis in human cancer as well as mouse models, and support a physiologic role
for this source of OPN in transformation.
OPN is clearly important for the growth promoting effects of senescent fibroblasts
as OPN depletion from senescent fibroblasts drastically reduces growth of preneoplastic
cells. However, our data indicate that recombinant human OPN (rhOPN) does not fully
mimic the enhanced preneoplastic cell growth observed when cells are grown in the
presence of senescent fibroblasts expressing OPN. The inability of rhOPN to recapitulate
the magnitude of preneoplastic cell growth observed in our coculture conditions raises the
possibility that other factors cooperate with fibroblast-derived OPN. Alternatively,
posttranslational modifications of stromal-derived OPN may be important. OPN is a
heavily modified protein that possesses metalloproteinases (MMP) cleavage sites [37].
Both protein modifications and cleavage impact OPN function [45, 46]. Interestingly,
analysis of our microarray data indicated that several MMPs are expressed at high levels
in senescent fibroblasts. Western blot analysis of conditioned medium obtained from
senescent fibroblasts revealed the presence of OPN species that were not present in our
rhOPN preparation, raising the possibility that one or more of these species mediates the
growth-promoting activities of senescent fibroblasts. In addition, despite the high levels
of OPN mRNA present within senescent fibroblasts, we did not detect the protein in the
cell pellets but instead were only able to detect OPN in the conditioned media of
senescent fibroblasts, indicating that a significant amount of the protein is present as a
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soluble factor within the extracellular space. Such data suggests that the presence of
OPN in the stroma of premalignant lesions such as papillomas may be underappreciated.
Our data and that of others [19, 20] support a role for senescent stroma in
preneoplastic lesions but does not preclude its involvement in the later stages of
transformation and cancer development. Interrogation of our senescent microarray data
revealed a prominent inflammatory profile, which could facilitate recruitment of other
components of the microenvironment in addition to impacting the ECM, bone marrow
cell recruitment, and angiogenesis. Intriguingly, CAFs also express many of these
factors, some of which are able to promote vascularization by recruiting endothelial cells
[47]. Furthermore, a recent report demonstrates that CAFs secrete extracellular matrix
tracks on which tumor cells can migrate, thus facilitating metastasis [48]. While OPN
has been shown to be important for metastasis and is a validated prognostic marker in
human neoplasias, it was recently shown to function as a systemic instigator by
mobilizing and recruiting bone marrow-derived cells to the tumor stroma [49].
Interestingly, immunohistochemical analysis of xenografts arising from injections with
stromal cells in the absence of OPN revealed a decrease in immune infiltration compared
to those arising in the presence of OPN expressing stromal cells. This observation raises
the possibility that senescent stromal-derived OPN affects recruitment of cells of the
innate immune system potentially through bone marrow mobilization. These results
underscore the importance of paracrine signaling and the interplay between different
components of the tumor microenvironment at multiple stages of transformation.
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Figure 2.1 Senescent fibroblasts stimulate the growth of preneoplastic cells. A,
continued passage (RS) and treatment with 100 ug/ml bleomycin (SIPS) induces robust
senescence characterized by induction of senescence associated β–galactosidase (SAβGal) staining. Magnification 20X. B, fibroblasts undergoing RS or SIPS stimulate the
in vitro growth of HaCaT keratinocytes expressing click beetle red luciferase. HaCaT
cells were plated on lawns of young, RS, or SIPS fibroblasts and their growth was
measured by relative luciferase activity. Wells containing HaCAT cells and young
fibroblasts were set to 1. Fold increase in growth over wells with young fibroblasts is
plotted. p<0.05. C, HaCAT cells were injected alone or with young or senescent
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fibroblasts (RS) into NOD/SCID mice. For each injection, 2.5x105 HaCaT cells were
coinjected with 7.5x105 fibroblasts. In vivo imaging of luciferase activity was used to
assess HaCaT cell growth weekly. Each line represents the average photons/sec for 6
independent injection sites. Student’s t test at day 28, p < 0.05. D, Hematoxylin and
eosin stains of histological sections obtained from xenografts injected with HaCaT cells
alone or in the presence of young or senescent fibroblasts (top to bottom). Magnification
10X.

51

Figure 2.2 Analysis of the senescence transriptome reveals significant overlap
between cells undergoing replicative and stress-induced premature senescence. A,
microarray analysis of young BJ fibroblasts and BJ fibroblasts undergoing RS or
bleomycin induced SIPS. Hierarchical clustering of consistent transcript alterations
across all conditions and replicas are plotted. B, Venn diagram plots genes that
significantly overlap in fibroblasts undergoing RS and SIPS versus young. C, Gene
ontology analysis (GO) of upregulated classes in cells undergoing RS and SIPS compared
to their younger counterparts (i.e. Immune & Inflammation, Mitogens & Regulation of
Proliferation, Extracellular Matrix & Secreted Factors). D, Fold upregulation of select
genes in senescent fibroblasts (SIPS) was confirmed by qRT-PCR. Expression in young
fibroblasts was set as one for all genes.
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Figure 2.3 Senescent stroma is present in preneoplastic lesions following DMBATPA treatment. A, Representative SA-βGal staining of frozen tissue sections reveal
robust staining within the stromal compartment (n=3). Skin treatments are as follows: (1)
AA, acetone followed by weekly acetone treatment (2) DA, DMBA followed by weekly
acetone treatment; (3) AT, acetone followed by weekly TPA treatment; (4) DT, DMBA
followed by weekly TPA treatments. B, Immunohistochemical analysis of osteopontin
(OPN) in kidney sections from wild type (C57/B6) and OPN deficient mice.
Magnification upper panel 10X and lower panel 40X. C, OPN and p16 expression in
DMBA/TPA induced papillomas (upper panel) and associated skin (lower panel). Serial
paraffin embedded tissue sections were stained with antibodies against OPN and the cell
cycle inhibitor p16. Magnification 40X. (n=2 of 6).
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Figure 2.4 Senescent-derived OPN is necessary for preneoplastic cell growth. A,
Stable knockdown of OPN expression by viral-based RNAi is revealed by qRT-PCR.
OPN mRNA expression in senescent fibroblasts transduced with a control hairpin
(shSCR) was set to 100%. Three independent short hairpins targeting OPN (shOPN-7, 8, -9) resulted in robust knockdown of OPN mRNA. B, Western blot analysis (IB) of
OPN immunoprecipitations (IP) from cultured supernatants obtained from young (-) or
senescent (+) fibroblasts mock transduced, transduced with a control hairpin (shSCR), or
transduced with hairpins targeting OPN (shOPN-7, -8, -9). Recombinant human OPN
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(rhOPN) is included as a reference. C, RNAi directed loss of OPN does not affect the
induction of senescence upon bleomycin treatment. SA-βGal expression in i) young, ii)
SIPS, iii) shSCR SIPS, iv) shOPN-7 SIPS, v) shOPN-8 SIPS, and vi) shOPN-9 SIPS BJ
fibroblasts. Magnification 40X. D, Upper Panel: Quantification of HaCAT cell growth
when plated on lawns of fibroblasts. Preneoplastic cell growth was measured by relative
luciferase activity and wells where HaCAT cells were plated with young BJ fibroblasts
were set to 1. OPN expression was depleted in senescent BJ fibroblasts by one of three
independent hairpins (shOPN-7, -8, -9) to greater than 95% in all cases. A control
hairpin (shSCR) was used as a negative control. Depletion of OPN expression reduced
preneoplastic cell growth to levels observed in cells plated with young fibroblasts.
#p<0.05. Lower Panel: Quantification of N.p.c.T cell growth when plated on lawns of
fibroblasts. Loss of OPN expression (shOPN-7, -8, -9) resulted in reduced growth similar
to that observed with HaCaT cells shown in upper panel. #p<0.05.
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A

B

Figure 2.5 Loss of OPN expression in senescent fibroblasts results in reduced
preneoplastic cell growth in vivo. Fibroblasts were uninfected (young and SIPS),
infected with a control virus (shSCR, sSCR SIPS are young and senescent fibroblasts,
respectively), or a virus that knocks down OPN expression (shOPN, shOPN SIPS are
young and senescent fibroblasts, respectively) greater than 95%. Relative to SIPS
fibroblasts, knockdown of OPN resulted in a significant reduction in growth of HaCaT
xenografts in NOD/SCID mice (n=3). *p=0.003, #p=0.04, and Φp= 0.06. B,
Immunohistochemical analysis of xenografts obtained from mice injected with HaCaT
cells and senescent fibroblasts expressing a control hairpin (shSCR) (upper panel) or a
hairpin targeting OPN (shOPN) (lower panel). Shown are Hematoxylin and Eosin
(H&E) and staining for the immune markers CD45 and F4/80, which identify leukocytes
and macrophages, respectively. Photos focus on stromal sections showing CD45 or
F4/80 positive staining. Magnification for H&E, 10X and for CD45 and F4/80, 40X.
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Figure 2.6 OPN is sufficient to stimulate the growth of preneoplastic cells. Cell
growth was measured by relative luciferase activity and the growth of cells receiving
BSA alone was set to 1. A, addition of 100 ng/ml of rhOPN was sufficient to stimulate
the growth of HaCaT cells. #p<0.05. B, addition of 100 ng/ml of rhOPN was sufficient
to stimulate the growth of N.p.c.T. cells. *p=0.05.
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Supplemental Figure S2.1 p16 positive cells are present in the stromal compartment
following treatment with TPA. Immunohistochemistry in skin sections from mice
treated with DMBA or TPA alone, or with DMBA-TPA. Mice were treated with DMBA
followed by weekly acetone treatment (DA), acetone followed by weekly TPA treatment
(AT), or DMBA followed by weekly TPA treatments (TA). Frozen skin sections
(exposed to the same treatment as shown on Figure 3) were stained for p16 – a senescent
marker. Magnification 40X.
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Supplemental Figure S2.2 Senescent stromal cells are present within papillomas that
arise following DMBA-TPA treatment. SA-βGal staining of frozen tissue sections
obtained from papillomas reveals the presence of senescent cells within the stromal
compartment. Magnification 20X.
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Supplemental Figure S2.3 Multiple OPN species are found in conditioned medium
obtained from senescent fibroblasts. The gel is a longer exposure of the gel pictured in
Figure 4 that reveals the presence of at least two unique OPN species that are not present
in the rhOPN preparation.
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Abstract
Senescent fibroblasts stimulate preneoplastic cell growth in a paracrine fashion
due to an altered secretory profile enriched in growth factors, cytokines, and
extracellular-remodeling enzymes that are regulated at the transcriptional level by
mechanisms not yet clearly defined. This expression pattern has been referred to as the
senescence-associated secretory phenotype (SASP). Here we demonstrate that the
regulation of one of these key molecules, osteopontin (OPN), is unaffected by the
inhibition of p53, Rb, and NfκB and independent of the senescence-associated DNA
damage response. To identify putative regulators of OPN, I screened several fragments of
the human OPN promoter for maximum activity in senescent fibroblasts. We identify a
responsive region that contains a canonical Myb binding site and other recognition
motifs. Based on this sequence, I conducted an RNAi screen, which revealed several
factors that impacted OPN transcription. Because chromatin modulation has been
implicated in senescence regulation, I also included several chromatin-modifying genes
in the screen. Based on the results from this screen I propose that changes in chromatin
structure directly stimulate SASP activation. Indeed treatment with agents that induce
chromatin relaxation in the absence of overt DNA damage induces a robust SASP.
However, OPN in contrast to two other members of SASP, IL6 and IL8, does not require
ATM signaling nor NfκB activation. These findings indicate that components of the
secretory profile, while coordinately upregulated, are controlled by distinct
transcriptional pathways.
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Introduction
Senescence is a permanent cell cycle arrest that is most often characterized by a
flattened morphology, increased senescence-associated β-galactosidase (SA-βgal)
activity and the appearance of facultative heterochromatin domains known as senescenceassociated heterochromatin foci (SAHFs) [1]. While growth-arrested, senescent cells
remain metabolically active. In addition, extensive microarray analysis has revealed that
senescent cells display a programmatic change in their transcriptional profile
characterized by a pronounced inflammatory signature, increased production of growth
factors, and enhanced secretion of extracellular matrix (ECM) remodeling enzymes.
Because a large percent of the proteins modulated upon the activation of senescence
represent secretory proteins, this program has been referred to as the senescenceassociated secretory pathway (SASP) [2].
Work from several groups in recent years has demonstrated that such gene
expression alterations not only enforce the cell cycle arrest in the originating cell but
impact the surrounding milieu as well [3-5]. Similar to cancer-associated fibroblasts,
senescent fibroblasts modulate the tumor microenvironment in several ways: secreted
mitogens stimulate premalignant epithelial cell growth in vitro and in xenograft models
[6, Bavik, 2006 #385, 7-9], ECM remodeling enzymes such as matrix metalloproteinases
affect branching and migration [10] and other factors including cytokines promote
invasion [11, 12]. The ability of senescent fibroblasts to influence tumorigenesis has
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been documented convincingly in multiple systems; however, until recently, the
underlying mechanisms governing SASP in senescent fibroblasts were unknown.
One of the features of the senescent transcriptome is a pronounced inflammatory
signature [5, 13]. Members of this inflammatory core such as IL6, IL8, and CXCR2 are
required for the induction and maintenance of senescence in addition to acting as
paracrine effectors of tumor growth. Regulation of such chemokines in other settings by
NfκB and C/EBβ appears to operate in senescence as well. In fact, both transcription
factors occupy promoters of IL6 as well as other cytokines in vivo [4, 5]. RNAi-directed
silencing leads to abrogation of senescence and its associated transcriptome indicating
that IL6 enforces a signaling cascade that activates the senescence program [5]. This is
not the first instance that these transcription factors have been linked to senescence.
Comprehensive biocomputational analysis of several murine tissues demonstrated that
the NfκB motif is one of the transcriptional modules most highly associated with ageing
[14]. Likewise, C/EBPβ cooperates with E2F to execute permanent arrest in mouse
embryonic fibroblasts [15].
The question remains how these transcription factors are activated in response to
senescence stimuli and subsequently directed to activate the transcriptional changes
occurring in senescence. It is conceivable that the DNA damage response (DDR), which
has been closely linked and possibly contributes to senescence [16, 17] triggers the
signaling cascade. Indeed, recent reports argue that a persistent DNA damage response
such as the one observed in senescence [17] is sufficient to activate the secretory
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phenotype. Signaling downstream of ATM (including NBS1 and Chk2) appears to
control a subset of the secreted factors, represented by IL6 and IL8 [11]. These results
are intriguing; however, forced expression of a cell cycle inhibitor induces senescence
and a paracrine response that stimulates preneoplastic growth in the absence of DNA
damage [6] indicating that DNA damage is not a prerequisite for SASP activation.
Activation of DDR leads to chromatin alterations that can have a profound impact
on numerous transcriptional pathways. Therefore, it is possible that the transcriptional
changes observed in senescent cells result from global chromatin modulation. There are
certainly several pieces of evidence that implicate chromatin remodeling in the
establishment of the senescent state. For example, several studies have reported the
appearance of SAHFs in senescent cells and shown that they occur at E2F promoters and
functionally repress proliferation [18-21]. Conversely, senescence is associated with
transcriptional activation generally attributed to chromatin decondensation. Loss of
heterochromatin associated with ageing is well documented in yeast [22] and other model
organisms [23] and in syndromes of premature ageing such as Hutchinson–Gilford
progeria syndrome (HGPS) [24]. Furthermore, a process known as relocation of
chromatin-modifying factors (RCM) [22] exemplified by the checkpoint-dependent
repositioning of sirtuins (yeast Sir2/mammalian SIRT1) to sites of stress induces
transcriptional deregulation that reflects an expression profile reminiscent of ageing [25,
26].
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In replicative senescence, histone deacetylase (HDAC) activity diminishes [27,
28], corresponding histone acetylation increases, whereas there is a decline in global
DNA methylation ([29] and references therein). Interestingly, treatment with HDAC
inhibitors such as sodium butyrate or trichostatin A induces senescence [28, 30-32]
arguing that chromatin relaxation plays a causative role in senescence. Although the
reported chromatin changes occur globally, individual promoters are uniquely modified
(e.g. cell cycle inhibitors [33, 34]) and only the expression of a subset of genes is altered
in senescence [35] suggesting the existence of a targeted transcriptional program rather
than global transcriptional alterations.
OPN is a multifunctional signaling molecule [36]. Originally identified in cancer
cells [37], the physiological function of OPN is linked to matrix integrity and bone
maintenance [38]. However, extensive research has implicated OPN in every stage of
transformation and has led to its classification as a prognostic factor for several
malignancies [39-43]. We have previously reported increased levels of secreted OPN in
senescent fibroblasts and identified it as a critical mediator of stromal-epithelial
interactions in tumorigenesis [9]. Given its diversity in signaling, it is not surprising that
OPN is under the control of a variety of transcriptional factors that are cell type specific
[44]. However, how OPN is regulated in senescent cells remains unknown.
Here we report that OPN upregulation in senescence is independent of the p53
and Rb pathways. Contrary to IL6 and IL8, whose concomitant overexpression is
controlled by NfκB, OPN is insensitive to NfκB signaling. Furthermore, while we
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observe a robust activation of the DNA damage response upon the induction of
senescence, we found that inhibition of ATM had no impact on the activation of OPN.
Importantly, treatment with an agent capable of directly perturbing chromatin structure in
the absence of DNA breaks was an equally potent senescence inducer that led to OPN
and SASP activation. I assessed the activity of several fragments of the human OPN
promoter in young and senescent fibroblasts thus identifying a particular region that is the
most responsive in senescence. Using the most responsive OPN promoter fragment, I
conducted an RNAi-screen to identify putative transcription factors involved in the
regulation of OPN in senescence. Together our results indicate that the senescent
secretory phenotype although characterized as a collective transcriptional response, is
under various layers of regulation with chromatin playing a central role.

Materials and methods
Cell lines and treatments. Human foreskin BJ fibroblasts and 293T cells were grown as
previously described [9]. Human fetal lung IMR90 fibroblasts were grown in MEM
media supplemented with 15% non-heat inactivated FBS (Sigma, St. Louis, MO). Human
AT fibroblasts (GM09607) were purchased from Coriell Institute (Camden, New Jersey)
and grown under the same conditions as IMR90 fibroblasts. Fibroblasts were mock or
Bleomycin sulfate-treated (100ug/ml, Sigma, St. Louis, MO) for 24 hrs to induce
senescence. Replicatively senescent fibroblasts were obtained by continuous passage.
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After 72 hr serum-starvation, RNA was collected using TRIzol (Invitrogen, Carlsbad,
CA). Actinomycin D (Sigma) was added to the cells after bleomycin treatment. For
sodium butyrate (Sigma), cells were incubated with two fresh changes of 4mM for 72 hr.
Plasmids. The pBabe-IκBα-mut construct [45] was purchased from Addgene (Boston,
MA plasmid 15291). The NfκB promoter luciferase construct, NF-κB5-luc and pGL3Renilla were a kind gift from David Piwnica-Worms (Washington University, St. Louis,
MO). Two shRNA plasmids targeting the human ATM gene sequence were provided in
the pLKO.1 plasmid (sequences found on Mission shRNA website; Sigma, St. Louis,
MO). Human p27 cDNA was cloned in pBabe-puromycin. The pBabe-p53-DD and
pBabe-DK constructs were provided by Robert Weinberg (Whitehead Institute,
Cambridge, MA). Human OPN promoter constructs [46] were kindly provided by Dr.
Paul Kuo (Duke University, Durham, NC)
Real-time PCR. Standard protocol was followed for cDNA and RT-PCR using the
following primers (IDT, Coralville, IA):
OPN F - TTGCAGCCTTCTCAGCCAA; R 5’- AAGCAAATCACTGCAATTCTC,
GAPDH, F -GCATGGCCTTCCGTGTCC, R 5’-ATGCCAGCCCCAGCGTCAAA
IL6, F-ACATCCTCGACGGCATCTCA-3’, R -TCACCAGGCAAGTCTCCTCA
IL8, F -GCTCTGTGTGAAGGTGCAGT-, R –TGCACCCAGTTTTCCTTGGG
SIRT6 F-AGGATGTCGGTGAATACGC R- AAAGGTGGTGTCGAACTTGG
H2A.X F- GGCCTTTCACATCAGCTCTC R- ATTGCCGAGTGAGTTTTGCT
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TIP60 F- AACCAGGACAACGAAGATGAGT; R- GTGATCTGGACCGGGATTGG
ATM (Taqman, ABI, Carlsbad, CA cat.# Hs01112317-g1).
Luciferase Assay. Cells were co-transfected with pGL3-Renilla and NF-κB5-luc or OPN
promoter fragments using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Readings
were performed with a Dual-Luciferase Reporter Assay (Promega, Madison, WI).
Western Blot Analysis. Fibroblast cell pellets were lysed in 100ul of RIPA buffer
(50mM HEPES pH 7.4, 150mM NaCl, 1% Triton, 1M EDTA, 10% glycerol) and protein
was quantified by the Bradford Protein Assay (Bio Rad, Hercules, CA). The following
primary antibodies were used: p421 (a p53 hybridoma supernatant kindly provided by
Robert Weinberg [Whitehead Institute, Cambridge, MA]) at 1:100; Cdk4 (Santa Cruz
Biotechnologies, Santa Cruz, CA) at 1:200; β Actin (Sigma, St. Louis, MO) at 1:10,000;
γ-actin (Sigma, St. Louis, MO) at 1:5000; γH2AX (Upstate, Billerica, MA) at 1:1000 and
detected by the appropriate HRP-conjugated secondary antibodies (Sigma, St. Louis,
MO).
Virus production and retroviral infections. Virus preparation as previously described
[9].
Immunofluorescent staining. Fibroblasts were plated on coverslips, serum-starved
overnight and fixed with 4% paraformaldehyde (Electronic Microscopy Services,
Hatfield, PA). After permeabilization with 1% TritonX-100, the samples were stained
with the following primary antibodies: γH2AX (Upstate, Billerica, MA) at 1:300 and
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phospho-ATM (Cell Signaling, Danvers, MA cat.# 4526) at 1:500, for 1.5 hr at room
temperature. Specific staining was detected by fluoro-conjugated secondary antibodies
(Invitrogen, Carlsbad, CA).
Senescent-associated β-galactosidase. Staining was performed on cells as previously
described [47].
Results
We previously performed microarray analysis on young, replicatively senescent
(RS) and stress-induced prematurely senescent (SIPS) BJ fibroblasts and observed
marked differences in their expression profiles [9]. This work led us to focus on
understanding the role of one of the upregulated proteins in senescence – OPN, in the
cross-talk between fibroblasts and epithelial cells. Indeed, we found that OPN was
necessary to stimulate the in vitro and in vivo growth of preneoplastic keratinocytes.
Given the significance of OPN in this model and the importance of the other senescent
secretory proteins, we investigated how OPN expression was regulated in senescence.
Treatment with bleomycin, a DNA damaging agent precipitates the onset of senescence
and the associated transcriptional changes in a similar fashion to replicative senescence
[9]. Both BJ and IMR90 fibroblasts experience a robust upregulation of OPN mRNA
upon induction of senescence with bleomycin treatment (Figure 3.1A). To confirm that
such upregulation reflects an increase in de novo transcription, we examined OPN levels
in senescence in the presence of actinomycin D, a well-characterized transcription
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inhibitor [48].

The classical OPN upregulation associated with senescence was

significantly reduced in the presence of actinomycin D (Figure 3.1B) indicating that
indeed OPN is regulated at the transcriptional level.
p53 and Rb are essential for the induction and maintenance of senescence via
transcription of cell cycle inhibitors and repression of proliferation genes respectively
[49]. Furthermore, OPN was identified as a direct transcriptional target of p53 [50]. To
investigate whether p53 and Rb activity were required for OPN mRNA upregulation in
senescent cells, we introduced a dominant negative p53 tetramerization domain (p53-DD)
[51] and a cyclin dependent kinase 4R24C (Cdk4)-cyclin D1 fusion protein (DK) [52] that
effectively block activation of p53 and inactivation of Rb respectively (Figure 3.2A).
Neither abrogation of p53 nor Rb reduced OPN transcript upon the activation of
senescence. On the contrary, in the absence of p53 or Rb, OPN basal levels in young
cells increased and they were augmented further upon induction of senescence. This
suggested that p53 and Rb not only are irrelevant for the senescence-associated
stimulation of OPN transcription but they in fact suppress it (Figure 3.2B).

As

previously reported, IL6 and IL8 levels in senescence also increased when p53 and Rb
function was compromised (Supplemental Figure S3.1 and [2]), indicating that these
factors are similarly affected by the p53 and Rb pathways in senescence.
NfκB is a master regulator of cytokine production in inflammatory responses [53]
and recently it was invoked in the transcriptional control of SASP [4, 12]. Like IL6,
OPN can participate in processes characterized by chronic inflammation [54] and NfκB
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can directly activate its transcription under certain conditions [55]. Therefore, it was
plausible that NfκB directly activated OPN in senescent cells. NfκB is classically
trapped in the cytoplasm in a complex with IκB α , which upon stimulation is
phosphorylated leading to degradation, thus liberating NfκB and allowing it to translocate
to the nucleus and activate transcription of its target genes [56]. To evaluate the
importance of NfκB in the transcriptional activation of OPN in senescence, I blocked its
signaling in young and senescent cells by expressing a mutant of IκBα that cannot be
phosphorylated (IκBα-mut) [45] (Figure 3.2C). In agreement with previous reports [4],
we found that NfκB activation is essential for the upregulation of IL6 and IL8 in
senescence (Figure 3.2D). In contrast, OPN levels remained unperturbed upon inhibition
of NfκB (Figure 3.2D). Because the expression of the mutant precedes the induction of
senescence, it indicates that NfκB signaling is not required for the initiation or the
maintenance of OPN levels in senescence.
Having established that neither the p53 or Rb pathways nor activation of NfκB
played a role in the upregulation of OPN in response to the activation of senescence, we
next turned our attention to the putative role of DDR. Senescence is characterized by a
robust and persistent DNA damage response [17] (Figure 3.3A) that includes activation
of the ATM kinase [49] and ATM activation, which has previously been linked to the
control of SASP [11]. To address whether ATM activation was required for the
upregulation of OPN in senescent cells we utilized ATM specific short hairpin constructs
to deplete ATM from our cells (Figure 3.3B). Despite a greater than 80 percent
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reduction in ATM mRNA, we did not observe a reduction in OPN levels upon the
induction of senescence (Figure 3.3C). In contrast, we found that the senescenceassociated upregulation of IL6 and IL8 was significantly impacted upon the inhibition of
ATM (Figure 3.3C) as previously reported [11]. These results indicate that OPN unlike
IL6 and IL8 is not controlled by DDR and NfκB signaling and represents divergent
regulation of the senescent secretory profile.
To confirm that the senescence-associated upregulation of OPN was independent
of DNA breaks, we induced senescence via overexpression of p27, an inhibitor of cyclinCDK complexes [57] or treatment with the histone deacetylase inhibitor sodium butyrate
(NaB) [31, 32]. In comparison to cells transduced with an empty vector, cells expressing
p27 cDNA assumed a flattened phenotype accompanied by positive staining for SA-βgal
and growth arrest (Figure 3.4A). Similarly, treatment with NaB resulted in lack of
cellular proliferation and a flattened phenotype consistent with senescence features (data
not shown and [30]).
To confirm that treatment with NaB did not cause DNA breaks, we carried out a
Comet assay, a sensitive technique utilized to detect DNA damage [58]. As expected,
treatment with NaB did not result in DNA breaks (data not shown) [30]. To further
corroborate these results, we also evaluated the levels of γH2AX, a phosphorylated form
of histone H2AX, widely recognized as an early marker of DDR and a platform for
assembly of repair factors [59].

Western blot analysis of an irradiated sample

demonstrated a robust increase in γH2AX as expected; while, neither p27 expression nor
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NaB treatment led to increased γH2AX levels in comparison to control cells (Figure
3.4B). Next, we examined OPN levels in cells driven to senescence by p27 expression or
NaB treatment. In both settings, we observed a robust induction of OPN despite the lack
of detectable DNA damage (Figure 3.4C and D). Notably, both IL6 and IL8 also
underwent a drastic increase in cells ectopically expressing p27 or treated with NaB
(Figure 3.4C and D) indicating that DNA breaks are not required for SASP induction.
Given that in bleomycin-induced senescence, ATM and NfκB are required for IL6
and IL8 regulation and NaB treatment activates ATM [81], we wondered whether the
same regulatory mechanisms are employed in NaB-induced senescence. Therefore, we
treated cells that express the IκBα-mut construct or AT cells (genetically deficient in
ATM activity) with NaB. Although NaB does not induce physical DNA damage, we
found that NfκB and ATM activity are mandatory for IL6 and IL8 expression; whereas in
agreement with earlier they do not affect OPN upregulation in senescence (Figure 3.5A
and B and data not shown). These results underscore the conserved nature of SASP
activation in senescence and suggest that chromatin is a central modulator of these
transcriptional pathways.
The human OPN promoter contains several binding sites for various transcription
factors [60], which are differentially engaged depending on the cell type and signaling
involved. The promoter elements required for its activation in senescence have not been
identified. Therefore, I examined a set of fragments derived from the human OPN
(hOPN) promoter [46] for their ability to respond in young and senescent fibroblasts.
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Transient transfection of serial deletions of the hOPN promoter revealed a defined pattern
of activation in senescence with a marked increase observed in the region above
nucleotide -135 (Fig. 3.6A) suggesting that crucial elements reside there. Scanning this
region for binding motifs yielded a repertoire of putative transcription factors (Figure
3.6B). We next investigated their role in OPN regulation by performing an unbiased
RNAi-screen. The work described above indicated that chromatin modifications induce
OPN and SASP activation. Therefore, I included in our RNAi screen both putative
transcription factors for which binding sites were present in the senescent-responsive
region of the OPN promoter and chromatin-modifying proteins previously implicated in
senescence. Most of the transcription factors with putative binding sites on the promoter
fragment (Figure 3.6B) were not detectable in senescent fibroblasts (data not shown);
therefore, it is highly unlikely they are required for OPN expression in this setting.
Hence, much of our effort has focused on chromatin-modifying enzymes. One exception
was the transcription factor c-Myb. I found that the senescence-responsive OPN
promoter fragment contains the sequence TAACTGT, which is an identical match to the
Myb-binding site (MBS) [61] (Figure 3.6B). Indeed, c-Myb binds the OPN promoter in
vivo in melanoma cells [62]. Appendix 1 contains preliminary studies suggesting a role
for Myb involvement in the regulation of OPN in senescence.
To assess the potential role of chromatin-modifying enzymes in OPN regulation, I
infected young BJ cells and induced senescence by blemoycin treatment. Surprisingly
three independent hairpins that depleted TIP60, a histone acetyltransferase that is
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required for ATM activation in response to DNA damage, by 50 percent had a dramatic
effect on OPN expression in senescence [63-65] (Figure 3.7A). In addition to ATM,
TIP60 targets several histones and is recruited to multiple promoters as a component of
various chromatin-modifying complexes, which could account for the effect on OPN
expression [65]. Additionally, I observed a significant decrease in OPN levels in
senescent fibroblasts expressing hairpins targeting SIRT6 and H2A.X (Figure 3.7B and
C). Two short hairpins that resulted in roughly 50 percent knockdown of SIRT6 at the
mRNA level decreased OPN expression by more than 70 percent (Figure 3.7B).
Sirtuins are well-characterized promoters of longevity and SIRT6 was shown to
deacetylate H3K9 and attenuate NfκB signaling [66, 67]. Depletion of H2A.X, which
like TIP60 participates in chromatin-mediated DNA damage sensing and repair [68, 69],
by 80 percent by two independent hairpins, likewise affected OPN transcription. It is
unclear in what capacity SIRT6 and H2A.X act in OPN activation; however, these results
clearly indicate that disruption of the chromatin architecture impacts OPN and likely
SASP activation in senescence.
Discussion
Senescent fibroblasts positively affect tumorigenesis in multiple models [6-8, 10,
70]. In efforts to understand how this is accomplished, several groups have examined the
expression profile of senescent cells and have uncovered a signature secretory program
enriched in growth factors, cytokines, and proteases termed senescence-associated
secretory phenotype (SASP) [2, 4, 5, 9]. Specific components of SASP have been
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directly implicated in senescent stromal-promoted tumorigenesis [5, 9, 10, 12]; however,
it is still unclear as to how SASP is activated in senescence. Initial findings demonstrated
that the transcription factors NfκB and C/EBPβ are essential for the upregulation of the
inflammatory cytokines and indeed directly bind their promoters [4, 5, 12]. Furthermore,
the DNA damage response (DDR) was invoked as an upstream inducer [11]. Indeed, the
abovementioned transcription factors can be activated in response to DNA damage [7173], although such relationship has not been described in senescence.

Utilizing

osteopontin (OPN) as a surrogate for SASP regulation, we found that SASP is not
characterized by a single transcriptional axis but is instead a diverse program activated in
response to chromatin changes.
OPN is significantly upregulated at the mRNA level in replicatively and
stress-induced senescent fibroblasts [9]. While originally identified as a component of
SASP by microarray analysis of early passage and senescent fibroblasts [9], sensitivity to
actinomycin D confirmed that OPN upregulation was transcriptional (Figure 3.1B) as is
the rest of SASP [2]. OPN is involved in a vast array of signaling pathways hence its
transcription is governed by multiple mechanisms in a tissue and context-dependent
manner [74]. We demonstrate that in senescence, OPN is not controlled by p53, Rb or
NfκB although p53 and NfκB have binding sites on the OPN promoter and do bind it in
vivo under certain conditions [50, 55]. The lack of p53 and Rb involvement is in
agreement with previous work showing that these essential pathways for senescence are
in fact dispensable for SASP activation [2] suggesting a decoupling of senescence
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induction and transcriptional activation of paracrine factors. Our findings reveal yet
another layer in SASP regulation. While NfκB and C/EBPβ directly activate IL6 and IL8
(Figure 3.2 and data not shown), they are not required for OPN upregulation in
senescence (Figure 3.2 and data not shown). Similarly, ATM knockdown has a profound
effect on IL6 and IL8 expression yet OPN increases to the same levels as in control cells
(Figure 3.3). Together, these results indicate that IL6 and IL8 are activated by ATM and
NfκB as it has been suggested [11, 12] and OPN is not.
Because OPN levels increase in senescence alongside IL6 and IL8, there must be
a common inducer of SASP. Given that bleomycin causes double-stranded breaks, one
can postulate that DNA damage triggers a transcriptional response and the ATM
involvement would justify this assumption [75, 76]. However, it is clear that OPN is not
regulated by the DDR, which begs the question whether DNA damage activates ATMindependent pathways or another upstream stimulus initiates separate signaling cascades.
Our experiments with senescent fibroblasts obtained by sodium butyrate (NaB) treatment
or ectopic expression of p27 demonstrate that in the absence of DNA breaks (and ensuing
signaling as measured by H2A.X phosphorylation, see Figure 3.4B), SASP is still
activated. Interestingly, ATM and NfκB are required for the upregulation of IL6 and IL8
(Figure 3.5A and B) in NaB-induced senescence as well, thus lending support to the
argument that DNA damage per se is not required to activate SASP. Histone deacetylase
inhibitors (HDACI) modify the chromatin mainly by inducing hyperacetylation of histone
and nonhistone proteins [77, 78] resulting in sustained transcriptional changes.
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Reportedly, HDAC activity decreases in replicative senescence exemplified by reduction
in levels of particular HDACs [27, 28]. In fact, such a mechanism has been invoked in
the chromatin changes observed in the prematurely senescent Hutchinson-Gilford
progeria syndrome (HGPS) cells [24].

However, we did not observe noticeable

differences in overall HDAC activity in senescent cells (data not shown). The data
presented here allow us to present a model where ATM activation in bleomycin- and
NaB-induced senescence occurs due to chromatin alteration (Figure 3.7D). It is known
that DNA breaks induce changes in the surrounding chromatin [79], which facilitates
signaling and repair; conversely, chromatin modifications trigger the DNA damage
checkpoint [80]. Indeed, HDACI activate ATM [71, 81] and our data argues that the
DDR required for SASP activation is not one emanating from breaks.
The interconnectedness between damage and chromatin easily explains the
phenotypes of the TIP60 and H2A.X-depleted cells – two proteins known to modify the
chromatin in the context of the DNA damage response [82, 83]. The question remains
how do they impact OPN given that its expression in senescence is unaffected by ATM.
Also, in NaB-treated cells there was no increase in γH2A.X arguing that this DNA
damage-dependent modification is dispensable for SASP activation. Given that depletion
of H2A.X results also in a decrease of IL6 and IL8 (data not shown); it argues for a
general effect on transcription of H2A.X deposition in chromatin possibly invoking other
modifications as well. TIP60 is part of the chromatin remodeling complex, NuA4, which
acetylates histones and transcription factors [84].
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Its yeast homolog, Esa1p, is

ubiquitously recruited to promoters throughout the yeast genome [85]. Given the highly
conserved nature of NuA4, the mammalian TIP60 may also act as a general cofactor for
basal transcription. Indeed, in mammalian cells TIP60 has been shown to couple its
activity to several transcription factors [65]. In this capacity, TIP60 (and H2A.X) may be
recruited to the OPN promoter during senescence and acetylate the histones or specific
transcription factors required for activation. It is less clear what role SIRT6 plays in OPN
expression. In mammalian cells SIRT6 deacetylates H3K9 [66]. Cells isolated from
SIRT6-/- mice have an enhanced expression of NfkB targets and undergo premature
senescence (SIRT6 null mice have a progeroid phenotype) [66, 67]. Under these
circumstances, SIRT6 activity inhibits the expression of pro aging genes; whereas in our
system, SIRT6 is necessary for OPN activation in senescence. Although, mouse and
human cells differ in the molecular execution of senescence [86], SASP appears to be
conserved between the two under physiological oxygen levels [87].
How p27 or other inducers of senescence alter the chromatin and lead to
activation of SASP is currently unknown. p27 is a cell cycle inhibitor, whose action
results in Rb hypophosphorylation [88, 89]. Rb impacts chromatin by recruiting
remodeling complexes to promoters [90], yet we demonstrate that Rb function is not
required for SASP activation (Figure 3.2B and Supplemental Figure S3.1). Therefore,
it is more plausible that p27 acts as the initial trigger of cell cycle arrest but the chromatin
modifications germane to senescence in fact modulate SASP. While it is unclear how
chromatin changes are instituted and maintained in senescence, there is ample evidence
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for their presence [18-21, 26, 91, 92]. It is conceivable that widespread chromatin
modifications impact promoter activity globally; however, this seems unlikely given that
our microarray results indicate the activation of only a subset of genes upon induction of
senescence. Furthermore, specific transcription factors (e.g. NfκB and C/EBPβ) are
required for the expression of a subset of SASP. Nevertheless, there is no single
transcriptional axis. It is unlikely that there are as many transcription factors activated as
the number of genes in SASP. Given that IL6, IL8 and several other inflammatory
cytokines are controlled by NfκB and C/EBPβ [4, 5], it is reasonable to speculate that
subsets of SASP have individual direct regulators. In fact, SASP contains different
clusters as defined by GO term analysis [9]. Our results indicate that SASP is not the
result of a single homogeneous transcriptional program and OPN represents a separate
cluster from the inflammatory cytokines [4, 5] and it will be interesting to uncover
activators of OPN and determine whether they control the expression of other proteins
belonging to the extracellular matrix cluster [9].

How chromatin in senescence serves as

a template for SASP activation and whether particular modifications are required is the
fundamental question to address in the future.
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Figure 3.1 Osteopontin is transcriptionally upregulated in senescence. A, Stressinduced prematurely senescent (SIPS) BJ or IMR90 human fibroblasts obtained by
bleomycin treatment were serum-starved for 72hr and analyzed for OPN mRNA levels by
quantitative real-time PCR (qRT-PCR). OPN expression in young cells was set to 1. B,
Effect of the transcriptional inhibitor actinomycin D was assessed on the senescenceassociated OPN upregulation. OPN expression in SIPS was set to 100 percent (n=2).
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Figure 3.2 p53, Rb, and NfκB are dispensable for OPN regulation in senescent
fibroblasts. A, Expression of a mutant form of p53 (p53-DD) or a cyclin D-cdk4 fusion
(DK) proteins in BJ fibroblasts is shown by Western Blot analysis. B, OPN levels were
measured by qRT-PCR in senescent BJ cells overexpressing p53-DD and DK.
Expression in young BJ cells was set to 1 (n=2). C, Relative luciferase levels of an NfκB
responsive promoter (pNF-κB5-luc) were quantified in young and senescent fibroblasts
expressing an empty vector or an IκBα super-repressor mutant (IκBα-mut) (n=2). D,
Same cells as in C were assayed for mRNA levels of OPN, IL6 and IL8. Levels of
expression in young cells was set to 1 (n=2).
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Figure 3.3 ATM regulates only a subset of SASP. A, Immunofluorescent images of
young and senescent BJ fibroblasts stained for the presence of γH2AX and
phosphorylated ATM (pATM) foci. B, ATM mRNA levels in BJ fibroblasts after the
introduction of a control hairpin (shSCR) or specific hairpins targeting ATM. Expression
in the control hairpin cells was set at 1 (n=2). C, Same cells as in B were assayed for the
mRNA levels of OPN, IL6, and IL8. Expression in the control hairpin cells was set at 1
(n=2)
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Figure 3.4 DNA breaks are not required for the upregulation of OPN in senescence.
A, Senescence-associated β galactosidase (SA-βgal) staining of BJ fibroblasts that
ectopically express p27. B, Immunoblot analysis of γH2AX levels in the cells described
in A. A sample irradiated with 5 Gy is included as a control. C and D, mRNA levels of
OPN, IL6 and IL8 in BJ fibroblasts that ectopically express p27 or treated with NaB
respectively (n=3).
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Figure 3.5 ATM and NfκB are required for IL6 an IL8 transcription in NaBinduced senescence. A, BJ fibroblasts overexpressing IκBα-mut were treated with NaB
and IL6 and IL8 mRNA levels were examined by qRT-PCR (n=2). B, AT cells were
treated with NaB and qRT-PCR was performed to examine mRNA levels of OPN, IL6,
and IL8 (n=2).
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Figure 3.6 Activity of the OPN promoter in senescence. A, Young and senescent BJ
fibroblasts were transiently transfected with progressively longer constructs of the human
OPN promoter driving the expression of luciferase. B, Transfac® analysis of the OPN
163 fragment identified several putative sites in the OPN promoter (table). Putative Myb
(MBS) binding sites are annotated on the OPN 2000 fragment.
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Figure 3.7 Chromatin modulators affect OPN expression. A, TIP60 mRNA (left) and
OPN mRNA (right) in senescent BJ fibroblasts expressing short hairpins targeting TIP60.
B, SIRT6 mRNA (left) and OPN mRNA (right) in senescent BJ fibroblasts expressing
short hairpins targeting SIRT6. C, H2A.X mRNA (left) and OPN mRNA (right) in
senescent BJ fibroblasts expressing short hairpins targeting H2A.X. D, Model of how
chromatin alterations may lead to activation of SASP – modified chromatin through
phosphorylated ATM (green) can activate NfκB, which directly binds the IL6 and IL8
promoters and induces the inflammatory subset of SASP. Other transcription factors
(TF) can be activated by chromatin modifications and subsequently lead to OPN
expression and possibly other members of SASP belonging to the same cluster.
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Supplemental Figure S3.1 p53 and Rb are not required for IL6 and IL8
transcription. Fibroblasts expressing either a truncated form of p53 (DD) or cyclinDcdk4 fusion construct (DK), which inhibits p53 and Rb respectively, were treated with
bleomycin and mRNA levels of IL6 and IL8 were measured by qRT-PCR (n=2).
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4.1 Summary
Our understanding of tumors as complex organs has increased our appreciation
for each component of the tumor microenvironment and its respective contribution to
tumorigenesis. Fibroblasts found within a tumor actively participate in the growth,
progression and metastasis of cancer cells. Senescent fibroblasts, which are permanently
arrested yet metabolically active, accumulate in tissue over time where they may promote
the proliferation and malignant conversion of preneoplastic cells. In chapter 2, I
investigate the relationship between senescent fibroblasts and preneoplastic keratinocytes
and identify the secreted multifunctional protein osteopontin (OPN) as a critical stromal
mediating factor. RNAi-directed reduction of stromal OPN leads to decreased growth of
preneoplastic keratinocytes in vitro and in vivo. Furthermore, I demonstrate the presence
of senescent stroma and associated OPN expression in the early stages of a chemical
carcinogenesis mouse model. OPN is part of a unique transcriptional profile activated
upon senescence induction. Given the significance of senescent stromal-derived factors
in tumorigenesis, I address the regulation of OPN and other members of the senescenceassociated secretory profile (SASP) in chapter 3. Although SASP is coordinately
upregulated in response to multiple stimuli inducing senescence, the downstream
mechanisms responsible for the transcriptional activation of particular subsets of SASP
are different. Work in chapter 3 illustrates the divergent regulation of OPN. I
demonstrate that unlike the best-characterized SASP factors IL6 and IL8, OPN is
insensitive to NfκB inhibition. Additionally, I examine the promoter of OPN and
uncover a putative role for chromatin modulators in the regulation of OPN expression in
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senescence. Below, I discuss the implications of my thesis work in the context of
senescence and tumorigenesis at large. Additionally, I deliberate on the outstanding
questions and how future studies may address them.

4.2 OPN as a Critical Senescent Stromal Factor
Osteopontin was identified several decades ago as a protein associated with
transformed cells [1]. Most of the subsequent work focused on its role in tumorigenesis,
where it has been implicated in various stages of transformation including survival,
proliferation, angiogenesis, and metastasis [2]. Numerous studies qualify OPN as a
prognostic candidate for several malignancies [3-7]. While OPN performs important
functions in bone maintenance, matrix mineralization, and calcification; the impact of its
loss is subtle as evidenced by the absence of any overt phenotypes in the OPN null mouse
[8, 9], suggesting the existence of compensatory mechanisms under normal physiological
settings. OPN’s role in pathological settings appears to be more significant. Indeed, OPN
baseline levels remain relatively low in most tissues unless there is a pathological
challenge, which typically causes an immediate and significant spike in OPN expression
thus classifying OPN as a general early stress responder [10]. Therefore, it is not
surprising that when OPN null mice are challenged by various stresses, they display
notable defects [9].
This is best illustrated by tumor studies. When OPN null mice are treated with a
two-step chemical carcinogenesis protocol, they have a delayed onset and lower
incidence of papillomas [11]. One explanation for this finding may be that the initiated
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keratinocytes require OPN for early clonal expansion and growth – a prerequisite for
papilloma formation. In fact, activation of H-Ras, which is the mutational target in this
model [12], leads to OPN transcription [13, 14]. However, data discussed in chapter 2
argues that additional properties of OPN may account for the delayed tumor phenotype in
the OPN null mice. I found that senescent fibroblasts, unlike their genetically identical
younger counterparts, express high levels of OPN. Examination of papillomas revealed
the presence of senescent stroma that expressed OPN (Figure 2.3). Importantly, I
observed senescent stroma in the skin of treated mice long before the emergence of
papillomas arguing that senescent stromal-derived OPN plays a role in the initial stages
of tumorigenesis. These findings could explain the delayed onset and lower incidence of
papillomas in the OPN null mouse given that we also showed that stromal-derived OPN
is necessary for the growth of premalignant keratinocytes (Figure 2.4).
Recently, it was shown that OPN is a member of a pro-inflammatory cancerassociated fibroblast (CAF) signature, which is responsible for recruiting macrophages
and promoting angiogenesis and tumor progression in a skin model of tumorigenesis
[15]. This report supports our observations of reduced immune infiltrate in xenografts
with fibroblasts expressing a short hairpin against OPN (Figure 2.5). Additionally, it
demonstrates that CAFs are similar to senescent stroma in that they are found in
dysplastic lesions again arguing that fibroblasts are an important contributor early on in
the transformation process. Given the importance of the stromal compartment in
tumorigenesis, these results raise the possibility that manipulation of the stroma before
any neoplastic changes occur may impact tumor formation.
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To this end, a conditional mouse model would be better suited to address the role
of OPN derived from different sources. To investigate the function of senescent stroma
in tumorigenesis, the laboratory has undertaken the creation of two different mouse
strains engineered to induce senescence exclusively in the stromal compartment via
ectopic expression of p27 (already shown to induce senescence in fibroblasts in vitro in
Chapter 3 and discussed below) or telomeric repeat factor 2 (TRF2) deletion, which will
be subjected to various tumorigenesis protocols including the two-step chemical
carcinogenesis described above. TRF2 is a component of the critical telomeric protective
complex known as shelterin [16] – once deleted leads to rapid telomere dysfunction and
cellular senescence [17]. Once these models have been fully validated, they can be
utilized to assess the role of OPN in the context of senescent stromal promotion of
tumorigenesis. While mating into the OPN null mouse does not exclude contribution
from other cell types, senescence will be induced conditionally in the stroma and a
comparison with the matched control will uncover any differences derived from the
absence of OPN in the senescent stromal compartment. Alternatively, a conditional
deletion of OPN in the fibroblasts would be the ideal model of study. All of the above
experimental paradigms are complex and time demanding yet important to parse out the
effects of OPN in tumorigenesis.
Our data indicate that OPN acts locally in a paracrine fashion by stimulating the
growth of preneoplastic keratinocytes; yet it has systemic effects reflected in the
recruitment of immune cells. This has also been demonstrated with tumor-derived OPN,
which attracts bone marrow-derived cells into indolent tumors thereby fueling their
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growth [18]. It is unclear whether senescent stromal-derived OPN accomplishes the
same task. The xenograft model is not robust enough to address this issue given that the
fate of the injected senescent fibroblasts is uncertain. However, the aforementioned
conditional models may provide a better platform for this purpose. There is more
impetus to study and target stromal-derived OPN given its significant local and systemic
impact.
OPN can affect multiple parameters of tumorigenesis and this depends on the cell
type and modifications present [19]. I found that senescent fibroblasts promote the
proliferation of preneoplastic keratinocytes in vitro as evidenced by higher BrdU
incorporation and unaffected apoptotic rates in the presence of senescent fibroblasts
compared to young fibroblasts (data not shown). Ongoing work in the laboratory has
confirmed this finding when examining the effect of OPN alone on keratinocytes’ growth
and further uncovering a putative role for the MAPK pathway as the downstream
mediator of OPN’s proliferative signaling. The main caveat of this approach is the
utilization of human recombinant OPN. Although OPN is extensively modified, it is
unknown whether these modifications recapitulate those found in the OPN produced by
senescent fibroblasts. OPN is a 34 kDa protein, yet it typically runs at a higher molecular
weight due to abundant phosphorylation and glycosylation [20], which is the case with
the senescence-derived OPN (Figure S2.3). Isolation and purification of OPN derived
from senescent fibroblasts would provide an ideal tool to study the signaling initiated by
senescent fibroblasts in their cross-talk with preneoplastic keratinocytes.
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4.3 Induction and Regulation of SASP
What controls the decision of a cell to enter senescence remains largely unknown;
however, some mechanistic insights have emerged in the recent years. Several reports
demonstrated that eroded telomeres, which trigger replicative senescence, are recognized
as sites of DNA damage and therefore elicit a persistent DNA damage response (DDR)
[21-23]. DDR initiation activates the downstream transcription factor p53, which
implements cellular arrest [24]. Remarkably, oncogene-induced senescence employs
DDR as well [25, 26] revealing a common underlying mechanism between replicative
and stress-induced senescence. In addition to p53, Rb represses proliferation by
recruiting the heterochromatin machinery to E2F promoters [27]. Indeed, senescence in
some cell types is accompanied by senescent-associated heterochromatic foci or SAHFs
[27, 28]. Both a persistent DDR and marked chromatin modulation appear to be required
for senescence [25, 29] although knowledge of explicit mechanisms is lacking.
In addition to permanent proliferative arrest, senescent cells are characterized by
an altered transcriptional profile [30], which is referred to as the senescence-associated
secretory profile or SASP [31] because it includes several chemokines, growth factors,
and enzymes that are secretory in nature and capable of altering the surrounding
microenvironment. Regulation of SASP is the subject of intensive research, which has
focused on whether the same mechanisms that govern cell cycle arrest also direct the
SASP transcriptional program.

I investigated this question by examining OPN

transcriptional regulation in senescence. Unexpectedly, neither p53 nor Rb activity were
required for OPN expression in senescence (Figure 3.2B). On the contrary, OPN levels
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were augmented further upon the induction of senescence in the absence of p53 or Rb,
following the same trend as other SASP components including the well characterized IL6
and IL8 [31]. Since SASP promotes tumorigenesis in a paracrine fashion, it has been
argued that p53 acts as a tumor suppressor in a non cell-autonomous fashion in addition
to its classic cell-autonomous role [31].
Although p53 is one of the major targets of the DNA damage response (DDR)
[32], it is not required for SASP transcription [31]. However, DDR activates multiple
pathways in addition to p53 [33]. Furthermore, there is precedence for DDR activating
transcription of genes that are not involved in the downstream repair process [34, 35].
Therefore, I assessed the impact of DDR on OPN expression in senescence and found
that ATM inhibition did not affect OPN levels (Figure 3.3). Conversely, expression of
IL6 and IL8 was dramatically reduced in agreement with previous results [36]. This was
one indication that OPN transcription is subject to different regulation and that SASP
consists of distinct transcriptional clusters. Another element that set OPN regulation
apart was the insensitivity to NfκB activity, which was crucial for IL6 and IL8 expression
(Figure 3.2). Therefore, senescence-associated OPN transcription, unlike IL6 and IL8
does not require the actions of ATM or NfκB.
To confirm the general applicability of these findings, I induced senescence by
different methods that unlike bleomycin treatment do not induce DNA breaks. When
cells are exposed to sodium butyrate (NaB) a histone deacetylae inhibitor (HDACI) or
when they ectopically express the cyclin inhibitor p27, they become senescent. Given
that OPN is a SASP factor that does not require DNA damage for its activation, we
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expected a similar upregulation in p27- and NaB-induced senescence to that detected in
bleomycin-induced senescence. Indeed, I did observe that OPN transcription was
increased following both of these treatments (Figure 3.4C and D). Strikingly, IL6 and
IL8 also underwent a significant upregulation in both settings indicating that they are not
strictly induced by DNA breaks. However, we found that IL6 and IL8 transcription
failed to increase when ATM or NfκB were abrogated in NaB-treated cells, arguing that
these pathways are still critical in the absence of DNA damage (Figure 3.5).
Mechanistically, DNA breaks induce sumoylation of NEMO (a modulator of classic
NfκB signaling), which is recognized by ATM and further modified by phosphorylation,
removal of SUMO, and ubiquitination. The resultant complex is exported out of the
nucleus and subsequently binds the IKK complex thus allowing the release of NfκB and
its translocation into the nucleus [37].

It is conceivable that NfκB activation in

bleomycin-induced senescence, which incurs damage occurs through this pathway. One
can examine the interaction between ATM and NEMO and determine the effect of the
ATM-phospho mutant NEMO [37] on IL6 and IL8 expression in senescence. On the
other hand, HDACI activation of NfκB is attributed to continuous acetylation of p65,
which reduces the affinity of NfκB for its negative regulatory IκB complex and ensures
continuous signaling [38] and ATM may be involved in some cells [39]. This is testable
by utilizing acetylation mutants of p65 and rescuing with HDAC3 (the HDAC
responsible for deacetylation of NfκB).
These experiments begin to address the fundamental question of what signaling
nexus is active in senescence and how it triggers SASP. DDR and chromatin modulation
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are inextricably linked. DNA breaks cause remodeling of the surrounding chromatin
[40]; however, the transient changes in chromatin architecture that accommodate DNA
damage sensing and repair cannot be responsible for SASP given that transient DNA
damage is not sufficient for SASP induction [36]. Conversely, chromatin modulation
causes activation of DNA damage kinases [41]. Moreover, it is important to note that
DNA damage signaling (e.g. activation of DDR kinases such as ATR) in the absence of
breaks can induce senescence [42]. In our experiments with NaB we failed to detect
DNA breaks by the sensitive COMET assay (data not shown and [43]). Furthermore, we
did not detect any increases in γH2AX levels upon NaB treatment arguing against any
evidence of ongoing DNA damage signaling (Figure 3.4B). Significantly, we do not
observe phosphorylated ATM aggregated in foci in NaB-treated cells; instead there is a
diffuse pattern indicative of activation in the absence of breaks ([41] and data not shown).
One can surmise from the above observations and the requirement of ATM for IL6 and
IL8 transcription in NaB-treated cells (Figure 3.5) that ATM is activated in a breakindependent manner.
Addressing how chromatin remodeling triggers SASP activation is a much more
difficult task due to the unknown nature of modifications occurring in senescence.
HDACI induce histone hyperacetylation that leads to changes in gene expression patterns
[44-46]. Interestingly, in replicative senescence HDAC1 protein levels are lower [47,
48]. Similarly, HDAC1 levels and corresponding activity are also lower in cells obtained
from patients with premature ageing syndromes such as Hutchinson-Gilford progeria
syndrome (HGPS), which are characterized by gross defects in nuclear architecture and
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chromatin [49]. Reduction of histone deacetylase activity and silencing of specific
heterchromatic complexes (NuRD) alone recapitulates the nuclear defects of HGPS cells
arguing that chromatin modifications playing a causative role in premature ageing [49].
Significantly, gene expression changes including upregulation of extracellular matrix
(ECM) genes occur in HGPS cells [50]. We have observed a modest OPN upregulation
in HGPS cells (data not shown), which prompted me to investigate whether a similar
mechanism operates in senescence. However to date I have not detected any significant
changes in HDAC1 levels or overall HDAC activity in bleomycin-induced senescence
(data not shown) suggesting that other components of the chromatin machinery may be
involved.
Work done in model organisms provides an alternative hypothesis to
transcriptional alterations in ageing [51]. Sirtuins, which are NAD-dependent HDAC, are
well known promoters of longevity [52]. During genotoxic stress, sirtuins relocate from
their telomeric positions to sites of damage, where they contribute to the assembly of
additional chromatin factors. Once repair is accomplished, sirtuins return to their usual
location. This phenomenon is known as relocation of chromatin modifiers or RCM [53].
However, during normal ageing or chronic genotoxic stress, the spatial flexibility of
RCM decreases and sirtuins are stably relocated to promoters of genes typically
upregulated during ageing [53]. One of the transcription factors modulated by SIRT6 is
NfκB [54], which controls several age-associated genes [55] and at least a subset of the
SASP [56, 57]. Although the level of sirtuins does not change, their ability to respond
adequately to stress and maintain telomere stability is decreased presumably resulting in
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ageing phenotypes [51]. Notably, short hairpins that target SIRT6 significantly decrease
OPN levels in senescence (Figure 3.7). While classically sirtuins are implicated in
facultative heterochromatin formation and repression of transcription [53, 58], their
effects on gene expression can be variable depending on the target promoter. For
example, SIRT1-mediated deacetylation of FOXO3 favors activation of genes mediating
cell arrest but not apoptosis [59]. Thus, sirtuins could be occupying specific promoters
themselves as part of a chromatin complex and/or modifying the activity of transcription
factor(s) required for activation [59-63]. Additionally, SIRT1 deacetylates SUV39H1
increasing its activity [58], thereby possibly affecting senescence induction [29] and
indirectly SASP activation. Chromatin-immunoprecipiation for specific sirtuins or
examining interactions with putative transcription factors could clarify this issue.
How senescence induced by p27 overexpression activates SASP is unclear.
Chromatin modulation in this context has not been investigated. p27 arrests the cell cycle
by inhibiting cyclin/Cdk complexes ultimately leading to Rb activation [64]. Rb is a
well-characterized mediator of chromatin remodeling by virtue of its association with
several modifying complexes [65]. As previously mentioned, it is required for SAHF
formation in senescence [27]. However, experiments performed with cells expressing the
DK mutant [66] (Figure 3.2) negate any Rb involvement (the DK fusion protein should
block the activation of all pocket proteins including p107 and p130 [67]). p27 has other
non-cell cycle dependent functions and modifications by various kinases coordinate its
actions mainly outside the nucleus [68]. Paradoxically, p27 thus modified is usually
associated with proliferation and tumor progression [68]. Given that cell cycle arrest and

114

SASP induction appear to be independently regulated [31], it is possible that
noncanonical targets of p27 yet to be elucidated play a role in SASP activation.
Several lines of evidence suggest that independent of the inducer of senescence,
unifying mechanisms are in place to activate SASP. Global histone and specific
promoter analysis would be useful to determine whether particular chromatin
modifications correlate with SASP activation. Probing for various overall modifications
including methylation and acetylation of histones could lead to the identification of
potential key modulators of SASP. For instance, histone methyltransferase SUV39H1,
which trimethylates H3K9 is required for the induction of senescence [29]. H3K9me3 is
a repressive mark that mediates gene silencing in senescence including E2F-controlled
cell cycle regulators [27]. Acetyltransferases perform the opposite function and thereby
may activate SASP. Depletion of TIP60 – a HAT found in several chromatin modifying
complexes [69], decreases OPN levels in senescence (Figure 3.7). It will be interesting
to examine whether its HAT activity is required for OPN expression (upcoming
experiments will test more thoroughly the effect of a TIP60 construct mutated in its HAT
function) [70]. While promoter analysis of SASP factors is expected to confirm an open
chromatin configuration in senescence, particular marks may lead to the elucidation of a
specific modulator/complex, which can be validated by chromatin immunoprecipitation.
Whether particular chromatin modulations dictate transcription factor activation
in senescence is currently unknown. Our preliminary results invoke c-Myb as putative
transcriptional regulator of OPN in senescence since its depletion led to a decline in OPN
expression (Figure A1.3). c-Myb has a binding site on the OPN promoter (Figure 3.6B).
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Ongoing experiments will validate these results and determine whether c-Myb binds in
vivo upon induction of senescence by utilizing chromatin immunoprecipitation.
Independently of the result of the above experiment, the question remains as to
how these transcription factors are activated in senescence. There is no change in the
mRNA or protein levels of c-Myb (Figure A1.4 and data not shown) suggesting that
posttranslational modifications or conditional partnering is responsible. c-Myb is subject
to phosphorylation, sumoylation, ubiquitination, and acetylation [71], which can affect its
binding and/or transactivational activity. Probing for any of these modifications may
provide clues to its regulation in senescence. We have ruled out the involvement of
TGFβ in the activation of OPN transcription (Appendix 2); instead our results implicate
the MAPK pathways particularly Mek (Figure A2.5) in the activation of OPN expression
upon induction of senescence. We need to confirm preliminary results demonstrating
ERK activation in senescence and corroborate the effect of MEK inhibition on OPN
regulation by genetic mutants (e.g. MEK DN). Interestingly, c-Myb is a target of ERK
[72] suggesting an upstream regulator. Finally, we have demonstrated that OPN is not
under the same transcriptional control as IL6 and IL8, which begs the question whether
OPN belongs to a different SASP cluster. IL6 and IL8 represent the inflammatory
component of SASP [31, 56, 57] and it is not surprising that NfκB, a master
inflammatory orchestrator [73], regulates their expression even in senescence.
Conversely, OPN is a matrix-associated protein and extracellular matrix proteins are
significantly represented in the SASP [74, 75]. We have undertaken some preliminary
analysis to identify additional SASP factors that are regulated similarly to OPN. A large
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microarray study comparing young fibroblasts to senescent fibroblasts that express
hairpins targeting c-Myb or other transcription factors involved will address this issue in
a broader fashion and reveal any putative clusters.

4.4 Conclusions
The tumor microenvironment is a critical player in tumorigenesis. This work has
focused on the role senescent fibroblasts play in tumor initiation and progression. We
have identified osteopontin as a secreted protein enriched in senescent fibroblasts and
have demonstrated that it is required for the paracrine stimulation of preneoplastic cells
by senescent fibroblasts both in in vitro models and in xenograft studies. Such findings
are revealing given that we have identified senescent stroma in the early steps in
carcinogenesis in vivo and OPN expression by such stroma in early lesions such as skin
papillomas [74]. Continuing efforts are aimed at understanding how the senescent stroma
triggers the production of OPN and other SASP factors. We have excluded involvement
of well-characterized transcriptional pathways employed in senescence and have
demonstrated that SASP factors, while coordinately upregulated are subject to different
transcriptional activators. While we continue to investigate how OPN and other
senescent stromal factors are regulated, we will be able to understand better the complex
heterotypic relationships characteristic of tumors. Our work may expose at the molecular
level the link between increased cancer risk and ageing.
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Introduction and Results
Early studies on the c-Myb transcription factor led to its designation as a
hematopoietic lineage determinant [1]. However, further work demonstrated that Myb
participates in cell cycle progression, differentiation and oncogenesis ([2] and references
therein). Myb affects the expression of its target genes via direct binding to its cognate
sequence and/or interactions with specific partners including C/EBPβ [3]. Recently, it
was shown that c-Myb protein levels increase in late passage human fibroblasts possibly
contributing to enhanced protection against oxidative stress [4]. In Chapter 3, I identified
a fragment of the human OPN promoter that was consistently stimulated in senescence
(Figure 3.6A). This fragment contains the sequence TAACTGT, which is a canonical
Myb-binding site (MBS) [5]. Reportedly, c-Myb binds directly to the human OPN
promoter and drives its expression in metastatic melanoma cell lines [6]. In this
Appendix, I describe preliminary experiments that suggest a role for Myb in the
transcriptional activation of OPN in senescence.
To test the functionality of the MBS in the OPN promoter, we performed cotransfection experiments. Young and senescent fibroblasts transiently transfected with
OPN promoter fragment containing the MBS (OPN190) and c-Myb demonstrated a
robust induction of promoter activity arguing that c-Myb is a limiting factor in OPN
transcription (Figure A1.1). Next, we substituted several core nucleotides as well as
surrounding ones (labeled as MBS-mut), to determine the specificity of the sequence as a
target of endogeneous c-Myb binding. In line with the previous experiment, alteration of
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the core binding sequence abrogated activity of the reporter in senescent fibroblasts
strongly suggesting that this sequence is required for Myb binding in vivo (Figure A1.2).
To further examine the role of Myb, I employed lentiviral-based short hairpins to reduce
its levels in senescent fibroblasts. Upon RNAi-mediated depletion of c-Myb, we
observed a significant decline in OPN levels (Figure A1.3). To further validate these
results, we have obtained additional short hairpins that target Myb and are currently
investigating whether Myb binds the endogeneous OPN promoter in senescence utilizing
chromatin immunoprecipitations (ChIP). In conclusion, these results suggest that Myb
binds the OPN promoter in a sequence-specific manner and is required for OPN
upregulation in senescence.

A1.2 Discussion and Conclusions
To our knowledge, this is the first instance implicating Myb in the regulation of
OPN transcription in senescent fibroblasts. Although, it was reported that Myb protein
levels increase in late passage fibroblasts, we did not observe any differences between
young and senescent fibroblasts (Figure A1.4) [4]. This could be attributed to the mode
of senescence induction (stress-induced premature senescence versus replicative
senescence) or the cell lines used. At present, it is unclear how Myb’s activity in
senescence is regulated. Notably, Myb is subject to a variety of posttranslational
modifications [2], which can affect its DNA binding ability and/or transactivation activity
without altering protein levels.

p42(MAPK)-mediated phosphorylation of c-Myb

differentially modifies its transactivation activity in a promoter-specific manner [7].
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Likewise, acetylation of the Myb negative regulatory domain by CREB-binding protein
(CBP) enhances its affinity for CBP and Myb’s transactivation capacity [8]. There is
evidence for altered mitogenic signaling [9, 10] and global chromatin remodeling [11] in
senescence, which may lay the ground for differential activation of transcription factors
and we have shown (see Chapter 3) that chromatin is a central driver of SASP expression.
Examination of possible Myb modifications in our system may shed light on the
regulatory mechanisms invoked in senescence.
As mentioned above, c-Myb cooperates with multiple transcription factors and
regulatory complexes, which facilitates customized transcriptional responses. A classical
example is the interaction with CCAAT/Enhancer Binding Protein β (C/EBPβ) on the
established Myb-inducible mim-1 promoter [5]. Ectopic expression of both transcription
factors stimulates the full activity of the mim-1 promoter in fibroblasts, where it normally
is suppressed [12]. Furthermore, the synergistic effect is attributed to chromatin
relaxation and a long range interaction over an enhancer element located approximately
2kb upstream of the Myb-regulated boxes in the promoter [13, 14]. The OPN promoter
contains a cluster of C/EBPβ sites positioned at a similar distance from the MBS
characterized herein. It is noteworthy that C/EBPβ is overexpressed in senescence and
has been implicated in the transcriptional activation of SASP [15], which raises the
possibility of combinatorial switches driving senescence-associated OPN expression.
However, preliminary results suggest that C/EBPβ is not involved in OPN upregulation
in senescence, in contrast to IL6 and IL8. Ectopic expression of the LIP isoform, which
blocks C/EBPβ-driven transcriptional responses in a dominant negative fashion [16, 17],
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has no effect on OPN levels in senescence, while it abrogates the concomitant IL6 and
IL8 upregulation (data not shown). Myb can partner with other transcription factors
however [2]; therefore, it will be interesting to uncover interactions important for OPN
transcription in senescence.
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Figure A1.1 c-Myb activates the OPN promoter. Young and senescent fibroblasts
were transiently transfected with the OPN190 fragment driving luciferase (left) and WT
c-Myb (right). Luciferase levels were measured after 48 hours and expressed as percent
of pGL3-Renilla, used as a control for transfection efficiency (n=3).
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Figure A1.2 The MBS in the OPN promoter is functional. Young and senescent
fibroblasts were transiently transfected as in Figure A1.1 with the OPN190 fragment
containing the canonical MBS or OPN190 with the underlined residues mutated from
TAACTGTAGAT to TGCTAGTAGAC. Readings were performed as described earlier
(n=2).

131

Figure A1.3 RNAi-directed depletion of c-Myb decreases OPN levels in senescence.
Senescent BJ fibroblasts expressing a hairpin targeting Myb (causes a 60% reduction in
Myb levels) have lower OPN expression when compared to senescent cells expressing a
control hairpin (shSCR set at 100%) (n=3).
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Figure A1.4 No significant differences in Myb levels in young and senescent
fibroblasts. Lysates of young and senescent BJ fibroblasts were probed with an antibody
against c-Myb and γ Actin as a loading control.
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Introduction
Transforming growth factor β (TGF-β) signaling is multifaceted and results in
diverse physiological outcomes depending on the cellular context. Generally, ligands of
the super TGF-β family bind and activate a complex consisting of type I and II receptors,
which phosphorylates the receptor-regulated Smads (R-Smads) at the SSXS motif in the
C-terminus. Upon activation, R-Smads disassociate from the receptor, heteromerize with
the Co-mediator Smad (Smad4) and translocate into the nucleus where they drive
transcription in cooperation with other nuclear factors [1]. The linear pathway delineated
above comprises classical TGF-β-dependent signaling; however, R-Smads respond to
stimuli originating from other pathways in the cell including the mitogen activated
protein kinases MEK, p38 and JNK, which in a context-dependent manner can either
synergize, antagonize or operate independently of TGF-β [2]. TGF-β cytostatic
responses are well characterized; hence its designation as a tumor-suppressor in multiple
systems [3]. Consequently, the pathway, and specifically Smad3 – an R-Smad, has been
implicated in the regulation of senescence [4-6]. Furthermore, the TGFβ pathway
coordinates the expression of several genes during wound repair [7], a similar profile to
that encountered in senescence [8]. Interestingly, c-Myb is involved in the execution of
wound healing and its deficiency leads to impaired Smad3 activation during this process
[9] raising the possibility that these two pathways cooperate.
The senescent-associated transcriptome is enriched in proteins classified as
components of an extracellular matrix and growth factor cluster [10] reminiscent of a
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wounding profile [11]. Noticeably, there is a subset of bone fide TGFβ targets in our
microarray analysis that are upregulated in senescent fibroblasts, which is a key
remodeling orchestrator during wound healing (data not shown). Taking a closer look at
the OPN promoter, I observed a cluster of Smad-binding elements (SBE) [12] distributed
throughout and in close proximity to the region of interest described above (Figure
A2.1A). Therefore it is plausible that Smad3, a central transducer of TGFβ signals is
involved in the regulation of OPN in senescence.

Results and Conclusions
To test the above hypothesis, I examined OPN levels in fibroblasts with a
successful knockdown of Smad3 (Figure A2.1B). In my original analysis, three short
hairpins resulted in 87, 83, and 96 percent knockdown of Smad3. OPN levels in these
cells were reduced by 62, 90, and 89 percent respectively, suggesting that Smad3
regulated OPN expression in senescent fibroblasts. Unfortunately, in subsequent
experiments we were only able to deplete Smad3 with one of the three original RNAi
constructs, which maintained the effect on OPN expression (Figure A2.1C). Therefore,
to interrogate the putative involvement of Smad3 activity on OPN expression I obtained
an additional short hairpin, encoded by a different vector (pRS-shSmad3). Using pRSshSmad3, I achieved a slightly superior knockdown in Smad3 protein compared to the
original short hairpin (Figure A2.1B). Analysis of OPN mRNA levels in the pRSshSmad3 expressing cells did not reveal any significant loss of OPN expression (Figure
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A2.1C) raising the possibility that our earlier results were an off-target effect of the
Smad3 hairpin.
Given the inconclusive nature of the RNAi experiments, I interrogated the
putative implication of the TGFβ pathway in OPN expression in senescence via
pharmacologic inhibitors and genetic tools. The well characterized classical TGFβ
pathway relies on receptor-mediated activation of Smads – upon ligand binding, TGFβ
type II receptor (TβRII) phosphorylates the type I receptor (TβRI), which in turn
activates Smads [1]. Disruption of TβRI activity by a specific and potent inhibitor, SB431542 [13] successfully blocked TGFβ-induced plasminogen activator inhibitor type 1
(PAI-1) activation, which is a classic TGFβ-responsive gene [14] (Figure A2.2A);
however, upon induction of senescence, OPN levels increased in a typical fashion and
there was no impact on OPN expression in the presence of the inhibitor (Figure A2.2B).
Similarly, ectopic expression of a cytoplasmically truncated TβRII ([15] and Addgene
plasmid 12640), which acts in a dominant-negative fashion (Figure A2.2C), did not have
an impact on OPN upregulation (Figure A2.2D). To corroborate the absence of receptor
involvement, I employed a Smad3 construct that lacks the last four amino acids in the Cterminus (Smad3deltaC), which are indispensable for receptor-mediated phosphorylation
([15] and Addgene plasmid 12639). Upon senescence induction in the Smad3deltaCoverexpressing cells, the robust activation of OPN remained unperturbed (Figure
A2.3A). Together these results indicate that OPN expression in senescence is not subject
to canonical TGFβ-induced signaling. This is further substantiated by the lack of
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detectable differences in C-terminus phosphorylated Smad3 and TFGβ levels between
young and senescent fibroblasts (Figure A2.3B and C).
R-Smads have a proline-rich linker region that connects the well-conserved MH1
and MH2 domains [1]. Initially, multiple phosphorylation sites were suspected in the
linker based on its sequence. Several reports have now confirmed that the MAPK
pathways (ERK, p38 and JNK) [16-18] and other kinases [19-21] directly phosphorylate
Smad3 and affect its function. In most settings, noncanonical phosphorylation of Smad3
channels the input of multiple signaling pathways into TGFβ-driven responses; however,
this does not preclude TGFβ-independent activation of such nonreceptor kinases and
subsequent Smad activation [2]. Given that Smad3 appears to operate independently
from TGFβ receptor-mediated signaling in our system, I examined whether other
pathways implicated in its activation, were involved. When senescent fibroblasts were
incubated with chemical inhibitors targeting MEK (U0126) [22], p38 (SB 203580) [23]
and JNK (SP600125) [24] either separately on in combination, we observed a significant
decrease in OPN levels (Figure A2.4A) suggesting that MAPK signaling influences OPN
upregulation in senescence.

In agreement with this, we observed differential

phosphorylation of the linker region of Smad3 in senescent fibroblasts. There is a modest
increase in phosphorylation of residues S204 and S208 in senescent fibroblasts, which are
known targets of MAPKs (data not shown).
To test whether these specific phosphorylated residues are important for OPN
expression in senescence, we obtained a Smad3 construct that is mutated in all four
residues implicated in MAPK signaling labeled as Smad3-EPSM [25].
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Ectopic

expression of the Smad3-EPSM construct had no effect on OPN expression in senescence
arguing that these residues are not required for signal transduction in senescence.
Finally, to rule out any involvement of the Smad pathway, we obtained short hairpins
targeting Smad4, usually required for Smad3-mediated signaling [1].

Despite a

significant depletion of Smad4 with three independent hairpins knocking down between
60-80%, OPN levels were comparable to the control cells (Figure A2.5). In conclusion,
our results indicate that the TGFβ pathway is not involved in the regulation of OPN
transcription in senescence.
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Figure A2.1 RNAi-mediated depletion of Smad3 in senescent fibroblasts. A, The
human OPN promoter contains multiple Smad-binding elements (SBE) clustered together
[26]. B, Smad3 protein levels were compared by Western Blot analysis in BJ fibroblasts
expressing a control hairpin (shSCR) or control vector (pRS) to cells expressing hairpins
targeting Smad3. β-Catenin was used as a loading control. C, OPN mRNA levels were
determined by quantitative RT-PCR (qRT-PCR) in the same cells as in B (n=2).
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Figure A2.2 TGFβ receptor-mediated signaling is dispensable for OPN expression.
A, BJ fibroblasts were treated with 10ng/ml of TGFβ in the presence of vehicle or a
specific inhibitor (TBRi) for 48 hrs and PAI-1 mRNA levels were quantitated by qRTPCR. B, Senescent fibroblasts were treated with TBRi and OPN mRNA levels were
quantitated by qRT-PCR (n=4). C, BJ fibroblasts transduced with a dominant negative
allele of TGFβ receptor type II (TBRIIDN) were treated with TGFβ as in A and PAI-1
levels were measured by qRT-PCR. D, Senescence was induced in the same cells as in C
and OPN mRNA levels were measured by qRT-PCR (n=2).
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Figure A2.3 TGFβ canonical signaling does not affect OPN expression in senescence.
A, BJ fibroblasts were transduced with a dominant negative allele of Smad3 that lacks
four amino acids in the C terminus. OPN levels were measured by qRT-PCR in young
and senescent cells (n=2). B, Smad3 consists of two major domains, MH1 and MH2
separated by a linker region. pSmad3C recognizes the TGFβ-mediated phosphorylation
in the C terminus residues. Cyclophilin A was used as a loading control. C, TGFβ-1
levels were measured by an ELISA in young and senescent BJ fibroblasts (n=2).
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Figure A2.4 The linker region is not necessary for OPN activation in senescence. A,
Senescent cells were incubated with different inhibitors individually or in combination
(see text) for 72 hr. OPN mRNA levels were measured by qRT-PCR (n=3). B, OPN
mRNA levels were measured in young and senescent BJ fibroblasts transduced with a
point mutant Smad3 (see text) (n=2).
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Figure A2.5 Smad4 depletion has no effect on OPN expression. Senescent fibroblasts
expressing three independent short hairpins targeting Smad4 (left) were examined for
OPN levels by qRT-PCR (right) (n=2).
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